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Abstract 
Skin regeneration and wound management in the Bio-Pharma industry has been an area with 
constant research and new product development. The range of products includes foams, 
sheets, sprays, powders, hydrocolloids and gels. Majority of these products that exist in the 
market are collagen based products. However, using collagen products is very expensive and 
could also have long term risks on patient¶VKHDOWK. Furthermore, they do not regenerate the 
skin to its original shape and texture and thus leave a scar post treatment. 
As an alternative to these collagen based products, a more cost effective gelatin based skin 
regenerative product is being developed using cutting edge technology. The new product also 
promises complete healing of the burnt surface without retaining any marks or scars on the 
patient.  
This research explores the newly developed Skin regenerative product at a macro level, with 
operations, marketing and cost objectives included. The market analysis includes specifics to 
the Indian market and the focus is mainly on the Wound and Skin management of the Bio-
Pharma market. The different stages of the product life cycle and phases of clinical trials are 
analysed. Potential market segments and niches for the new product are identified and by 
using competitive benchmarks, the product is analysed for customer applications.  
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Chapter 1: Introduction 
1.1. Background 
Research Councils UK (RCUK) has announced £12 million of funding for collaborations 
between British universities and institutions in India, China, and the UK. Three large-scale 
UK-India collaborations have been agreed as part of this scheme, and will be jointly funded 
by the RCUK and the Department of Science and Technology (DST), India. As a part of this 
major project by the two governments a two-year grant of £1.5 million has been made to the 
University of Nottingham, the Indian Institute of Management, Bangalore, and the Indian 
Institute of Technology, Kanpur. The three partners aim to create a step-change in 
collaborative innovation in target identification, drug discovery, drug delivery and 
manufacturing. They will build on existing collaborations with the goal of producing clinical 
and commercial benefits from patent protected research (BioSpectrum, 2009). 
As a part of this initiative, a team from IIT Kanpur is working on several ground breaking 
researches XQGHUWKH³6FLHQFH%ULGJH3URMHFW´EDQQHU7KHUHDUHVHYHUDO%LR-Pharma products 
that are being developed under lab conditions in collaboration with University of 
Nottingham. The primary focus of this research is to explore the market and product that is 
being developed for Skin Regeneration & Wound Management.  
1.2. Aims & Objectives 
There are several players in the market who specialize in the wound and skin care 
management, therefore, the primary focus of the research is to study the market potential for 
a new product entry of a skin regeneration template. This research is focused mainly on the 
Indian market although at the macro level the science bridge project is a tri-nation (UK, 
China and India) initiative. The research aims at understanding the Indian regulations, 
government policies and market potential for the new Bio-Pharma product. By understanding 
the product life cycle in a Bio-Pharma industry in India, the report aims at understanding the 
current position of the product in the life cycle, highlighting the challenges and providing 
suitable recommendations for a smooth role out into the market. 
The new skin regenerative graft template is one of its kind, it is gelatin based unlike its 
competitors¶ products that are all collagen based. The research aims at analysing the 
competitors¶ products, understanding the new product at a business level and critically 
evaluating it. Since the target market initially is in a developing country like India, the 
research aims at analysing the appropriate pricing for the product. 
1.3. Structure of the Report 
The report is structured in an analytical framework with a mix of both qualitative and 
quantitative data. Chapter 2 is an overview of previous literature on new product introduction 
in the pharmaceutical sector. The main topics of discussion are pricing of a new product and 
exploring the key aspects of supply chain in Bio-pharmaceutical (Bio-Pharma) industry. This 
section also explores tissue engineering at a macro level and more specifically the research 
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done till date on burn and skin re-engineering. Finally, the section concludes with the applied 
research done so far on treating burns (2nd and 3rd degree) and deep wounds. 
After a brief description on the methodology in Chapter 3, the report flows into the 
quantitative aspects of the research. Chapter 4 begins with the analysis of the pharmaceutical 
market and exploring why there is a shift of focus to India? The research then narrows down 
to Biotechnology and Bio-Pharma markets in UK, China and India. A detailed analysis on the 
regulatory environment in India is explored to understand the policies of Indian government 
in the Bio-Pharma sector and also the funding opportunities. The market for Clinical trials in 
India is carefully analysed to be prepared for any challenges and to mitigate risks for the new 
skin regenerative product. 
Before starting the analysis of the new product, a background on the layers of skin, burns and 
wound management is explained and the characteristics of the existing skin regenerative 
products in the market and their drawbacks are tabulated. Chapter 5 is a detailed description 
of the new skin regenerative product. This section has all the relevant data gathered during 
the interviews and field visits to hospitals, it mainly involves the analysis of the qualitative 
data. Based on the financial data gathered, a pricing for the new product is extrapolated. 
Chapter 6 contains discussion on empirical evidence as against the literature review on areas 
such as pricing, product life cycle and external factors that influence decision making. 
Chapter 7 contains the summary of the research for the new gelatin based skin regenerative 
graft with conclusion and recommendations. The report concludes by highlighting the areas 
for further research. 
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Chapter 2: Literature Review 
2.1. New Product Introduction 
,Q WKLV FRQWH[W µSroduct¶ means tangible products i.e. goods. The term µgoods¶ refers to 
physical, tangible products that can be owned, traded, and distributed to different places at 
different times without changing their identity. However, a product in a modern world can 
also be something very intangible such as a piece of software, a piece of knowledge or an 
algorithm or a formula (Saaksvuori, A, 2008). New Product Introduction could be defined as 
the launch process of a new product, which starts from the product idea and ends with the 
arrival of the product on the market (Immonen, A, 2008). 
The new product discussed in this research is a Bio-Pharmaceutical based product. The 
different phases in product life cycle are analyzed in chapters to follow. One of the strong 
arguments of the new product is the price competitiveness. Thus this section explores the 
literature on product pricing. 
 
Figure 1: Considerations in new product pricing.  
Source: The Product Manager's Handbook 
For example, the product would be highly differentiated if the target customers are not price 
sensitive, and competitive response is not expected, it is conceivable to charge a relatively 
high price. However, low price will be necessary if the price sensitivity is high, product 
differentiation low and competition is heavy. 
The book states that a rough business analysis will have been prepared prior to new-product 
proposal and a continually evaluated to make it more definitive as new information becomes 
available. Ideally it would be when significant milestones are achieved. The author argues 
that the product development team should include product specifications, composition of the 
project team, a PERT/CPM chart to find out the critical path with key milestones, target dates 
There are several things 
that need to be 
considered to estimate 
the target price of a 
product. Some of such 
factors are possibility of 
competitive attack, the 
price sensitivity of the 
market and the degree of 
competitive 
differentiation. The 
figure 1 adapted from 
'The complete product 
management resource' 
(Gorchels, L, 2000) is a 
tree diagram with the 
considerations in the 
new-product pricing.  
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and implementation schedules. The marketing plan should not only specify the planned short 
term and long term roll-ours but also have identified risk factors, and suggestions for 
minimizing risk. Finally, the financial analyses should be expanded to include more detailed 
income statement and cash-flow information than was available at the proposal stage. 
2.1.1. Supply chain of Pharmaceutical products 
The concept of supply chain management has evolved from a narrow perspective, related 
only to material flows, to a broader view, encompassing material, information, financial and 
technical flows, both within each organization and between organizations (Arshider et al., 
2008). Material flow and information are intrinsically connected in order to create service 
flows which are delivered to fulfill market needs (Mills et al., 2004). Thus, speed and 
accuracy are among the major concerns on managing information.  
The literature on supply chain management could mainly be classified into three different 
flows: materials, Information and financial assets (Sahin and Robinson, 2002). As per the 
studies, delivering goods at the right place at the right time and related services constitute the 
material flow. It also revolves on issues of logistics, purchasing, stock replenishment, 
recycling and remanufacturing. Research suggests that order information and its propagation 
along the chain could be classified as Information flow (Lee et al., 1997), and initiatives like 
quick response and e-commerce. However, the management of financial flow has received 
much less attention to date. Although it is present in studies on supply chain coordination 
with contracts (Cachon, 2004) 
Professor Davi Nakano and Marcelo Caldeira Pedroso (2009) did an in-depth case study on 
Pharmaceutical companies wherein technical flow needs to be managed apart from order 
information, using specially designed path. In Pharma industry customers do not have 
discretion over their purchasing decisions as they are dependent RQSK\VLFLDQV¶prescriptions. 
Therefore pharmaceutical companies need to keep physicians well informed about drug 
development, in order to create demand. Thus these researchers argue that there have to be 
two paths in their outbound supply chain: the main path, where goods and order information 
flow to and from the market, and a secondary path, where technical information flows to 
create demand. 
 
Figure 2: Demand generation in Pharmaceutical industry. Source: (Nakano. D, 2009) 
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The figure depicts two different paths: 
- A material path, where products, order information and financial assets are conveyed, and 
- A demand creating path, where technical information on drugs is delivered to physicians 
The technical information flows upstream from Bio-Pharma companies to physicians 
however, the order information flow is from customers to drugstores and eventually pharma 
companies. Sell-in represents the flow of material in the drugstore and sell-out represents the 
product outflow tRWKHSDWLHQWV7KLVGHPDQGLVJHQHUDWHGE\WKHVXUJHRQRUWKHSK\VLFLDQ¶V
prescription. 
2.2. Life cycle of a Bio Pharma product 
The potential of new technologies to increase the speed of bringing a product to market 
presents enormous opportunities. However, speed does not necessarily guarantee quality or 
therapeutic and commercial success. Development programs that are not founded on the 
principles of quality and rigor are destined for delay at best and failure at worst. Quality and 
not quantity must permeate every element of drug development. 
Markets and technologies are changing rapidly, cost pressures are increasing, regulatory 
authorities are more demanding, and product life cycles and time-to-market are shrinking. 
Even with greater efficiency in lead identification and optimisation, improvements will also 
need to be made in clinical development and the overall speed to market. Gaining and 
sustaining a competitive advantage requires that a company understands the entire value 
delivery system, not just the portion of the value chain in which it participates. It can ensure 
technology providers access to the critical capabilities needed to seize opportunities from the 
major market developments. By providing strategies on when and how to access those 
technologies, a technology roadmap can help companies to position themselves better for the 
future (Rinne, 2004). 
A research done by Amir Aslani (2008) indicates that the technology roadmap process starts 
with the endpoint or vision clearly in mind and then traces alternative technology paths to 
achieve it. This would need the organisations to have a roadmapping tool, the technology 
process and products that would require fulfilling the market demands. His research also 
explains the implementation of technology roadmaps that are both forward and backward 
looking, which are defined as follows: 
Backward Roadmapping: Backward Roadmapping involves in finding out how to reach a 
given target set by the marketplace. Ultimately, the Bio-Pharma products are utilised within a 
consequent patient population and are thus market driven. 
Forward Roadmapping: Developing of innovative Pharma products is largely technology-
driven. Thus, forward roadmapping is the process of building upon existing technologies until 
new targets appear.  
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Figure 3 represents different stages of a product life cycle of a Pharmaceutical drug. Target 
discovery, drug discovery and pre-clinical trials would take 7 years, and the drug 
development process, which include clinical trials would take aproximately another 7 years. 
It would also need another 2 years to clear all the regulations and fill the marketing channels 
before it could be felt in the market. 
 
Figure 3: Driving forces of drug discovery paradigm change (Source: Amir-Aslani, 2008) 
It could be challenging for any company to operate in this complex and uncertain 
environment. Therefore, through roadmapping, creative solutions to the technology issues 
and research needs could be identified. Technology roadmapping will also help a company 
optimize its strategic planning and business development framework (Phaal, 2004). 
The Technology push as shown in the above (figure 3) is caused by one of the following 
fields: Informatics, Chemistry or Biology. Developments in biotechnology have allowed the 
drug discovery industry to move from serendipity based research towards rational, evidence-
based approaches (Amir-Aslani, 2008). Technology pull would occur when the new bio-
pharma product fulfills the fundamental requirements, such as:  
x Satisfies unmet medical needs 
x Exhibits superiority over existing treatments 
x Safe with low adverse drug reactions 
The research by Amir-Aslani (2008) also emphasizes on the fact that linking technology 
capabilities to future market needs in a resource constrained environment and high investor 
expectations would be the driving forces in drug discovery. 
2.3. Tissue Engineering 
Tissue engineering is an interdisciplinary field which applies the principles and methods of 
engineering and the life sciences towards the fundamental relationships in normal and 
pathological tissue and the development of biological substitutes to restore, maintain, or 
improve function (Skalak R, 1988). 
7LVVXHV WKDW DUH HQJLQHHUHG XVLQJ WKH SDWLHQW¶V RZQ FHOOV KDYH WKH SRWHQWLDO WR RYHUFRPH
current problems of replacing lost tissue function and offer new therapeutic options for 
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diseases where currently no options are available. Tissue engineering technology can play a 
vital role in the future management of pediatric patients. The primary intention of all 
approaches in tissue engineering is the functional or structural restoration of tissue through 
the delivery of living elements which become integrated into the patient. Rapidly emerging 
field of tissue engineering presently uses a combination of cell based and matrix based to 
achieve new tissue formation (Saxena, 2005). 
Cell and cell based techniques: 
In cell based techniques, isolated and disseminated cells are injected into the blood stream or 
a specific organ of recipient. The cells transplanted using such injection methods will utilize 
the blood supply for nutrients and the ground substance provided by the host tissue as a 
matrix bed for attachment, reorganization and desired growth (Matas AJ, 1996). 
Cell encapsulation techniques: 
In this concept for cell transplantation, the cells are cultured and encapsulated in a semi 
permeable membrane that isolates the cells from the body. However, at the same time the 
semi permeable membrane, which allows the diffusion of nutrients and wastes, prevents 
macromolecules such as antibodies and immune cells from accessing the transplant (Rozga, 
1994). 
2.3.1. Tissue engineering using open systems of cell transplantation  
 
Figure 4: Schematic representation of  
the process of tissue engineering  
This cell polymer construct then incorporates itself into the recipients own tissue. Therefore 
the approach to tissue engineering is to attach isolated cells to porous polymeric templates 
has been developed (figure 4). 
Biocompatible polymer matrices: 
An in-depth research done by Amulya K. Saxena in the Pediatric Surgical University Medical 
Center, Munster, Germany revealed few key characteristics that have to be prominent in an 
efficient biocompatible polymer matrix. His research findings revealed the following: 
Polymer matrices used in tissue-engineered devices need to be biocompatible and have been 
designed to meet the nutritional and biological needs of the cell populations involved in the 
formation of new tissue. The next important feature is that the material should be re-
The primary goal of the open system of cell 
transplantation is to engineer new tissues by having 
the transplanted cells in direct contact with the host 
with the intention of providing a permanent natural 
solution to the replacement of lost tissue. Cells for 
transplantation using this technique are attached to 
matrices consisting of natural materials or synthetic 
polymers and then implanted to the host. 
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absorbable so that they leave a completely natural tissue replacement. Furthermore, polymer 
matrices should be reproducibly processable into desired structures and shapes and be able to 
retain their shapes after implantation in the host.  
Finally, the surface should interact with the transplanted cells to allow retention of 
differentiated cell function. Materials on the other hand that do not possess the above 
properties or are non-reabsorbable carry a permanent risk of infection (Christiana AG, 1997). 
The most commonly used materials as substrates or encapsulating materials in the field of 
tissue engineering are either synthetic polymers such as lactic-glycolic acid or 
polyacrylonitrile polyvinyle chloride, or natural materials such as collagen, hydroxyapatite, 
or alginates (Saxena, 2005). 
2.3.2. IN-VITRO Culture systems 
In vitro (in the lab) culture systems that are mainly used for tissue engineering are Static Cell 
Cultures and Bio Reactors. During the field visit to IIT, Kanpur, it was found that Bio-
Reactors were used for tissue engineered products. 
 
Figure 5: Dynamic cell culture or bioreactor concept for tissue generation using 3-D polymers 
 Source: http://www.jiaps.com 
Seeding of cells on 3-D biodegradable polymers in cell culture or flow bioreactor gave the 
opportunity to study tissue development, tissue regeneration, and tissue repair in vitro. 
Investigators have attempted to study the properties of almost all mammalian cell types under 
in vitro conditions. Knowledge obtained from different disciplines has evolved from primary 
animal research to clinical trials.  
Since the focus of this report is mainly on skin regenerative templates for wounds and burn 
care, the present status of skin structural and fictional tissue has been described below: 
Burn and burn related injuries are known to be associated with severe morbidity and 
mortality. In preclinical models, a cellular dermis has been populated with keratinocytes and 
fibroblasts and has been tested as skin substitute (Medalie DA, 1996). Biosynthetic analogs 
of skin, on the other hand have combined cultured skin cells with polylactic polyglycolic 
fabric, collagen sheets, and collagen-glycosaminoglycan sponges to provide skin re-
placements. This approach involves the in vitro culture of keratinocytes obtained from small 
Bioreactors: Bioreactors are dynamic cell 
culture systems that allow more control to 
generate larger volumes of cells when 
compared to conventional static-culture 
techniques. (Figure 5) The flow of tissue 
culture medium and their mixing within 
bioreactors can be controlled to enhance 
mass transfer of nutrients, gases, and 
metabolites in order to regulate the size and 
structure of the tissue being generated. 
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skin biopsies of burn patients. The rapid expansion of the keratenocyte population is achieved 
by cultivating keratinocytes on a feeder layer of irradiated fibroblasts (NIH 3T3) in 
association with certain media components. Although this method could be used to cover 
extremely large wound; a disadvantage, however, is that 3-4 weeks are required for cell 
expansion (Saxena, 2005). 
Another approach to fabricate skin, utilizes human neonatal dermal fibroblasts grown on 
degradable polyglycolic acid polymers. In this method selective cultures of dermal fibroblasts 
are inoculated into the porous reticulations of the substrate. In case of severe burn injuries 
involving all the skin layers, the graft is placed directly on the wound bed and a skin graft 
(cultured epidermal autograft) is placed above. This graft then vascularizes to form organised 
dermis like tissue. Furthermore, the addition of a dermal matrix to epithelial tissue engineered 
replacements adds the theoretical advantage of a thicker, more durable graft (Tinois E, 1991). 
2.4. Research work on burns 
There have been several studies done on the restoration of skin after a burn (2nd/3rd degree) or 
a wound. Most of the studies were done on products based on collagen or synthetic material. 
The area of gelatin being used as an alternative for collagen and indepth research into 
complete healing of the skin is still evolving. However, on analysing the research done on 
restoration of burnt skin there were was one crucial point which was evident in most of the 
work done:  
      While partial-thickness burns (1st and 2nd degree) have the ability to heal on their 
own while restoring relatively normal skin architecture, full-thickness burns (3rd degree or 
deep wounds) do not. Full-thickness burn injuries that destroy both the epidermis and dermis 
produce irretrievable skin loss, since completely destroyed dermis does not regenerate. 
Although, a full-thickness burn wound may heal with a contracting scar tissue base and an 
overgrowth of thin epidermis, it lacks many of the normal structures and basic functions of 
skin. Temperature regulation, sensory perception, excretory function (through sweating), and 
metabolic activities such as the formation of Vitamin D, to mention but a few, are either 
severely compromised or completely lost (Chuong. et al,  2002). Thick and hypertrophied 
scarring is often the hallmark of burn healing. 
Most burn surgeons interviewed during this research have pointed out the fact that skin 
grafting is most widely used to get a best outcome for the treating full thickness burns. 
Unfortunately, there is obviously only a limited amount that can be donated willingly from 
other parts of the body for transplantation. This therefore led researchers to explore either 
temporary skin substitutes or permanent skin substitutes (Jones, 2002). 
Skin substitutes as a group, include a collection of varied topically applied agents that offer 
not just simple protective covering but also healing a burn. Such substitutes include products 
that have inherent healing properties of their own or have added biologically active 
substances, presumably able to advance wound healing (Hansbrough JF, 1998).  They could 
either be sourced from intact human skin (called Allografts), animal skin (called Xenograft) 
or a combination of biological and manmade materials.  
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The most commonly used Allograft substitutes is frozen cadaver skin. Although Allografts 
KDYH KHDOLQJ SURSHUWLHV LW HYHQWXDOO\ VXFFXPEV WR UHMHFWLRQ E\ WKH SDWLHQW¶V V\VWHP ZKHQ
immune competence is restored. Various animals have been tried and tested for Xenografts. 
$PRQJWKHVHWKHEHVWVXLWHGIRUWKLVSXUSRVHLVIUR]HQSLJ¶V skin. However, it functions only 
as a temporary substitute or burn cover (Eisenbud D, 2004). Therefore the search for a true 
skin substitute is an ongoing process because of the inherent difficulties with Allograft and 
Xenograft. 
A major development of skin substitutes came from Burke et al (1981) and the development 
of Integra® (Integra Life Sciences). According to Ravage, the development of Integra was 
the result of a collaborative effort by these two pioneers that dates back nearly 30 years. It 
was only in 1996 that Integra was approved by the United States. The product is marketed as 
a dermal regeneration template that allows the ingrowths of fibroblasts, vascular tissue, and 
cells in a more organised fashion. The bovine collagen in the dermis are replaced by the 
SDWLHQW¶VFROODJHQDQGFHOOingrowths. The outer semipermeable silicone membrane functions 
as a protective barrier while revascularization and remodeling occur, much like normal 
epidermis. After maturation of the framework, this neodermis is covered by thin sheets of the 
SDWLHQW¶V $XWRJUDIW VNLQ WR FRPSOHWH WKH UHFRQVWUXFWLRQ ZZZ,QWHJUD-Is.com). This 
innovative discovery led to the outburst of many similar products. AlloDerm® (LifeCell 
Corp., Branchburg, NJ) is a dermal product that is made of specially treated cadaver skin. A 
proprietary process is followed to remove the epidermis and antigenic cells to leave a 
acellular, nonantigenic, dermal matrix (www.lifecell.com). Just as with Integra, AlloDerm 
must also be covered with skin Autografts to restore lost epidermis. 
Compared to the Allografts and Xenografts, dermal replacement products offer many 
advantages. Firstly, the scar after healing is markedly reduced. Therefore the scar contracture 
procedures are reduced. Another at least semiperPDQHQW VNLQ VXEVWLWXWH LV WKH SDWLHQW¶V
epidermal cells that are grown in the tissue cultures (discussed in above section). This 
technique allows the in-vitro FXOWLYDWLRQRIWKHSDWLHQW¶VHSLGHUPDOFHOOVE\PRGLILFDWLRQVRI
the innovatory techniques described by Rheinwald and Green in 1975. However, this epicel 
cannot be considered as a total skin substitute unless used in combination with some form of 
dermal reconstruction, since it only restores epidermis. 
Another product in the burn community often used as a temporary cover for burn is 
%LREUDQH 6PLWK 	 1HSKHZ ,W LV SHUKDSV HTXDOO\ XVHG DV RIWHQ DV VNLQ GRQRU VLWH
coverage. It is composed of two layers of silicone and a nylon mesh to which collagen is 
bonded (Smith & Nephew, 2009). Apligraf® and Dermagraft® (Advanced BioHealing) are 
two synthetic products that can be used as temporary skin substitutes, although their major 
utility appears to be in treating wounds other than burns. Apligraf is a man-made biological 
construct combining neonatal keratinocytes, fibroblasts, and collagen. Dermagraft uses either 
polygalactic or polyglycolic acid meshes combined with neonatal fibroblast to enhance 
wound healing (Advanced Bio Healing, 2009)  
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2.5. Summary 
For the new product introduction the product differentiation would be crucial in estimating 
the target price of the product. Factors like price sensitivity of the market, the degree of 
competitive differentiation and possibility of competitive attack must be carefully evaluated. 
The supply chain of a bio-pharma product could be classified as flow of material, information 
and financial assets. The researchers suggest that there need to be two paths where there are 
not just goods and order information flow but also technical information flow is important to 
create demand.  
Management gurus and research pundits also argue that it is not just the speed at which the 
products reach out to the customers but also the quality that permeates through every stage of 
the drug development that guarantees commercial success. In order to clear all the stages of a 
Bio-pharma's product life cycle, it is essential for a company to adopt strategies such as 
forward roadmapping or backward roadmapping. If the former strategy is applied then a 
technology push would be necessary by evidence based approach. However, if it is the later 
strategy, then technology pull would occur when the new product fulfills the fundamental 
requirements.  
The techniques in the technology of tissue engineering that could be adopted are either cell 
and cell based or cell encapsulations. Research has proved that in biocompatible matrices, 
characteristics such as absorption capacity, extent of natural tissue replacement, ability to 
retain its shape after implantation in the host and the ability to retain differentiated cells are 
extremely important to prevent risk of infection. During the process of creation of an efficient 
matrix, an in vitro culture system like a bioreactor would play a pivotal role. Time and again, 
treating burns (2nd and 3rd) and deep wound has been a challenging task. Several researchers 
and organisations have invested time and money to regenerate skin so that it attains its 
original shape and texture. Unfortunately, the fact of the matter is that partial thickness burns 
have the ability to heal on their own during restoration, but, full thickness burns do not. 
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Chapter 3: Methodology 
3.1 Methods for management research 
The method adopted in this management report is a looping flow of information between 
academic knowledge (the literature) and empirical evidence to understand the situation and 
environment. The research could be classified based on the quantitative and qualitative data. 
Each of these functions within different assumptions. But, the approach adopted in this report 
is applying the quantitative data to qualitative research and vice versa. 
3.1.1 Qualitative and Quantitative approaches 
Based on book written by Merriam, S. B (1988) on 'Research in education: A qualitative 
approach' qualitative approach could be defined as follows: 
Qualitative research is primarily process oriented, rather than outcomes or products. 
The interest is mainly in meaning how people make sense of their experiences, lives and their 
structures of the world. Therefore, it involves fieldwork to observe or record behaviour in its 
natural setting. It is more of a descriptive approach and involves understanding of the DFWRUV¶
perspectives. 
Quantitative research as defined by Creswell, J. W (1994) is the primary instrument for data 
collection and analysis. Rather than through interviews, questionnaires, or machines, data is 
interpreted through human instrument. The purpose is to understand the trends and predict the 
future. The data is reduced to numerical indices and portrayed in an objective way. 
Although some social science researchers (Lincoln & Guba, 1985) perceive qualitative and 
quantitative approaches as incompatible, others (Glesne, C., & Peshkin, A. 1992) believe that 
the skilled researcher can successfully combine approaches. 
3.2 Chosen methodology for this research 
Extensive secondary research was done to be abreast with the latest industry events and 
trends. Some of secondary information sources, where data was aggregated and analysed 
include: 
- National/Governmental statistics 
- International data (official international sources) 
- National and International Bio-Pharma associations 
- Broker and analyst reports 
- Company Annual Reports 
- Market Reports on Sector and Pharmaceutical industry 
- Business information libraries and databases 
Making revenue projections were based on the expected business strategies and financial 
analysis. Also, the Pharmaceutical industry standard was taken as benchmark to estimate the 
cost structure for the new product. 
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A qualitative and exploratory study, based on in-depth interviews, was designed to further 
understand how 2nd and 3rd burns are treated in India. Interviews were conducted in 
Bangalore, Chennai and Kanpur. Head of Department for Burns and duty surgeons of leading 
burns hospital- Victoria Nursing in Bangalore were interview on a Bi-weekly basis. A 
supplier of collagen based skin regenerating product in India was also selected for 
interviewing.  
Interviews were conducted between June 2009 to August 2009, few were fully tape recorded, 
while others were only hand notes. Important documents were collected after the interviews. 
Interviews were later transcribed verbatim. Also, to assist analysis, from hand notes, 
documents and transcriptions, a description case was written, validated by informants and 
discussed. Although the number of informants was limited, data saturation was clearly 
reached, as no new concept emerged during interviews. Permission was granted to quote 
excerpts from the interviews. 
3.3 Techniques to analysis 
The secondary data from various market researchers, news articles and online reviews were 
collated to understand the global Pharmaceutical market. This was then compared to the 
Indian market and the Bio-Pharma industry in India. Based on this, the market segment for 
Skin and Wound management was carefully analysed. Various products that currently exist 
within the market and their characteristics were studied.  
The information gathered by interviews about the existing product was crucial to understand 
WKH GRFWRUV¶ SHUVSHFWLYH DQG WR XQGHUVWDQG WKH ORRSKROHV LQ WKH SURGXFW OLIH F\FOH RI WKH
existing skin regenerating products. Interviews with the suppliers helped to understand the 
challenges in the supply chain. Finally, the interview with the team in Kanpur that is 
developing the product helped to understand the product as a whole and where exactly it fits 
in the product life cycle. The conclusions and recommendations are drawn based on the as is 
condition with appropriate assumptions. 
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Chapter 4: Market Research and Analysis 
To understand the Bio-Pharma market in India it is important to understand the current global 
Pharmaceutical market. Hence this section explores and analysis the international paharma 
market and narrows it down to the skin and wound regenerating products in the market. An 
attempt is made to focus on the Indian Biotechnology and Bio-Pharma market and gauge the 
market potential for the new skin regenerating product.  The role of clinical trials in India and 
its effect on the new product is also analysed.  
4.1. Market share 
The global pharmaceuticals, biotechnology, and life sciences industry group is composed of 
the pharmaceuticals market, the biotechnology market, and the life sciences tools and 
services market. 
The pharmaceuticals market includes only ethical drugs, ex-factory prices (the value at which 
manufacturers sell the drugs to distributors). The biotechnology market profile reviews 
companies primarily involved in the development, manufacturing or marketing of products 
based on advanced biotechnology research. The market value reflects revenues of companies 
within this market from product sales, licensing fees, royalties and research funding. The life 
sciences tools and services market is comprised of companies enabling the drug discovery, 
development and production continuum by providing analytical tools, instruments, 
consumables and supplies, clinical trial services and contract research services.  
 
Table 1: Global Pharmaceuticals, biotechnology, and life sciences industry group value: $ billion, 
2004-2008 Source: Datamonitor 2009 
As per 2009 Datamonitor Report for the global pharmaceuticals, biotechnology, and life 
sciences industry the group generated total revenues of $917 billion in 2008, representing a 
compound annual growth rate (CAGR) of 6.8% for the period spanning 2004-2008. In 
comparison, the European and Americas industry groups reached respective values of $269.1 
billion and $457.6 billion in 2008. The biotechnology segment generated revenues of $195.1 
billion in 2008, equating to 21.27% of the group's aggregate revenues. 
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Figure 6: Global Industry group segmentation: % share, by value, Source: Datamonitor 2009 
Pfizer is one of the world's largest research-based pharmaceutical company accounts for 5.3% 
of the global pharmaceuticals, biotechnology and life sciences industry group's value.  The 
company is engaged in discovering, developing, manufacturing and marketing of prescription 
medicines for humans and animals. The company operates in more than 150 countries across 
the world (Pfizer Annual Report 2008). GlaxoSmithKline (GSK), along with its subsidiaries, 
constitutes one of the major global healthcare groups engaged in the discovery, development, 
manufacturing and marketing of pharmaceutical and consumer health-related products. After 
3IL]HU*6.DFFRXQWV IRUD IXUWKHU$SSHQGL[RI WKH LQGXVWU\JURXS¶V UHYHQXH7KH\
have operations in approximately 117 countries, with products being sold in over 140 
countries (GSK Annual Report 2008). 
On further narrowing it down to Bio-Pharma sector, which is a part of Biotechnology, it 
accounts to 75.24% (Biospectrum-ABLE Survey 2005). Thus a large chunk of revenues in 
the Biotechnology industry accounts to the Bio Pharma sector. 
 
Figure 7: Bio-Pharma leads the way. Source:Biospectrum-ABLE Survey 2005 
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4.1.1. Why shift focus to India?  
Indian Pharma: 
Over the past few years the growth in the Indian pharmaceutical industry has been driven by 
rising disposable income, increased expenditure on healthcare, strong growth registered by 
Indian economy, changing diseases profile and regulatory forms. On overall basis, Indian 
companies outgrew the market at 11.9%; MNCs registered a growth of 5.5% (Cygnus Report 
2009). The industry has seen tremendous progress in terms of infrastructure development, 
technology base and the wide range of products manufactured. Demand from the exports 
market has been growing rapidly owing to the capability of Indian players to produce cost-
effective drugs with world-class manufacturing facilities. Bulk drugs of all major therapeutic 
groups, requiring complicated manufacturing processes, are now being produced in India. 
Pharma companies have developed Good Manufacturing Practices (GMP) compliant 
facilities for the production of different dosage forms. The Indian pharmaceutical industry is 
strengthening and mounting up the value chain. The industry, which was purely focused on 
reverse engineering, is now moving towards basic research driven market. 
With slowing growth rates in developed markets, the fast growing emerging markets have 
emerged as new sustainable sources of revenue growth. Although, the current pharmaceutical 
market values in these countries are not impressive compared to more mature markets, most 
are experiencing tremendous growth rates compared to the modest 2-5% growth seen in the 
US and Europe. India has emerged as a key destination for global pharma companies because 
of its superior growth prospects, improving socio-economic profile and regulatory reforms. 
These initiatives have made India one of the key focus markets for MNC pharma companies 
(Emkay Research, 2009). 
 
 
Figure 8: Growth in developing countries as against developed countries. Source: Emkay Research 
In CY08, the growth in the developed markets came down to 3% compared to 12% growth in 
the emerging markets. Going forward, Emkay Research on Pharma industry is projecting a 
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2% CAGR in developed markets compared to a 15% CAGR in the emerging markets over 
CY06-20E. India occupies a significant position in the world Pharma market ± especially in 
generics- 8% by volume (4th largest in the world) and 1.5% by value (13th largest). Export of 
generics accounts for 38% of the Pharma sector revenues (Virtus Global Partners, 2008). 
  
Figure 9: Pharma sales of Top 10 MNCs in India in 2008. Source: Prowess, Cygnus research 
 
Figure 10: Indian subsidiaries have outperformed their parent companies. Source: Emkay Research 
The above figure shows the pharma sales of top 10 MNCs in India it gives a clear indication 
on how the Indian subsidiaries of global pharma companies have outperformed their parent 
companies (albeit on a low base) in terms of sales and profit growth over the last 3 years. 
Most of the Indian subsidiaries have reported double digit growth in revenue, compared to 
the single digit growth of their parent companies. 
As the MNCs are struggling for growth in the regulated markets, they are willing to allocate 
more resources to their Indian subsidiaries. Of late, most of the CEOs of parent companies 
KDYH EHHQ YRFDO DERXW WKHLU IRFXV RQ WKH ,QGLDQ PDUNHW *6.¶V JOREDO FKLHI H[HFXWLYH
$QGUHZ :LWW\ KDVHPSKDVL]HG WKHJURXS¶V LQFUHDVHG IRFXVRQHPHUJLQJ PDUNHWV LQFOXGLQJ
India, for future growth. Similarly, Sanofi-$YHQWLV¶JOREDOFKLHIH[HFXWive, Chris Viebacher 
has indicated that the company is looking at consolidation opportunities in India. Pfizer and 
Merck & Co. have increased marketing efforts in developing countries in Asia, including 
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India. In order to scale up its operation in emerging markets, MNC companies are adopting 
multiple strategies such as  
a) scaling up of non-patented branded business 
b) launch of patented products 
c) divestment of non-core businesses 
d) scouting for company/ brand acquisition and 
e) charting country specific strategies. 
4.2. Bio-Technology and Bio-Pharma Markets 
The biotechnology market consists of the development, manufacturing and marketing of 
products based on advanced biotechnology research. The market value reflects revenues of 
companies within this industry from product sales, licensing fees, royalties and research 
funding.  
The Global Wound Management market grew to reach a value of $584 million in 2001 
(Datamonitor Report, 2001). This growth forecast by Datamonitor is at a CAGR of 17.8% 
between 2001 and 2011. It is evident that the potential for this market is very high due to the 
frequency of dressing changes and the slowness of the healing process. There are over 4 
million chronic wounds every year in the global market, which provides a substantial 
opportunity for advanced wound care products. These dressings are only beginning to come 
into favour in many countries though, and many practitioners remain uneducated about the 
benefits of practicing moist wound care. The wound management industry thrives on volume. 
In fact, their research also states that many countries have such low profit margins that only 
wound care giants that bundle their products, or tiny local manufacturers can afford to sell 
their products in these countries. 
 
Table 2: Global Wound Management Market share, 2001. Source: Datamonitor Report, 2001 
As per a 2001 report by Datamonitor on global wound management, Hydrocolloid are the 
most important type of wound management product in the Global Wound Management 
market, representing 36.1% of the market in value terms. Films and Foams each boast over 
20% of the Market. Amorphous Hydrogels and Hydrogel Sheets both contribute to the Global 
Wound Management market and have just over an 8% share between them. 
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4.2.1. Bio-Technology in China 
China has emerged as one of the key markets for global pharma companies. 10 countries 
contribute almost 85% of the total emerging markets sales. China is on the top among the 
emerging markets, contributing 25% of total emerging market sales and growing at the rate of 
27%. India's contribution among the emerging market sales is 8% and is growing at 11% 
(Emkay Research, 2009). 
 
Table 3:  Top 5 emerging markets in the Pharmaceutical sector, Source: GSK plc presentation 2009 
As per the 2009 research conducted by Datamonitor on the Chinese biotechnology market, it 
was found that the market generated a total revenues of $6.3 billion in 2008, representing a 
compound annual growth rate (CAGR) of 18.1% for the period spanning 2004-2008. Also, 
the medical/healthcare segment proved the most lucrative for the Chinese biotechnology 
market in 2008, generating total revenues of $5.8 billion, equivalent to 91.5% of the market's 
overall value. In comparison, the food and agriculture segment generated revenues of $421.6 
million in 2008, equating to 6.7% of the market's aggregate revenues (Datamonitor Report ± 
Biotechnology in China, 2009). 
One among the top players in the field, China National Biotech Group (CNBG) is a research-
driven biotech company that discovers, develops, manufactures and markets a broad range of 
human health products, including vaccines, blood derivatives, biopharmaceuticals, diagnostic 
reagents and others. The company is also a major player in China for the import and export of 
scientific and medical equipment and materials (www.cnbgint.com). 
4.2.2. Bio-Technology in UK 
The UK biotechnology market has posted healthy growth rates over the past few years 
however 2008 saw the market enter a brief decline. Despite this the market researchers are 
expecting a quick return to low level growth for the coming years. The UK biotechnology 
market generated total revenues of $7 billion in 2008, representing a compound annual 
growth rate (CAGR) of 5% for the period spanning 2004-2008. In comparison, the French 
and German markets grew with CAGRs of 8.2% and 7%, respectively, over the same period, 
to reach respective values of $4.3 billion and $5.3 billion in 2008 (Datamonitor Report, 
2009). 
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Table 4: United Kingdom Biotechnology Market Value: £/$ billion, 2004-2008 
There are two glaring market segments within UK which attract the Bio-Pharma companies. 
Firstly, the medical and healthcare sector has proved to be most lucrative for the United 
Kingdom biotechnology market in 2008, generating 69.2% of the market's overall revenues 
(Datamonitor Report UK Biotechnology Market, 2009). 
 
Table 5: UK Biotechnology Medical/health care Market Segmentation: %Share, by Value, 2008 
Secondly, on comparing UK with other European countries it accounts for 15.2% of the 
European biotechnology market's revenue. Although, it is second to Spain (16.6%), it still 
DFFRXQWVWRPDMRUSRUWLRQRIWKHFRQWLQHQW¶V%LRWHFKQRORJ\UHYHQXH:KLOHOLIHVDYLQJGUXJV
in UK might be expected to display very low price sensitivity, it is rare for purchasing 
decisions to be made by patients: insurance companies or state run health services will aim to 
keep their spending down, and may have enough scale (or legislative power) to exert pressure 
on prices. Overall, buyer power in the biotechnology market appears to be moderate. 
 
Figure 11: UK Biotechnology Market in whole of Europe: %Share, by Value, 2008. Source: 
Datamonitor 
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If we have to focus on the Bio-Pharma industry and Wound management in particular, the 
market segment has been very encouraging for the new skin regenerative graft. The market in 
the UK is rapidly evolving, due to the combination of high product availability and the use of 
the National Health System to promote these products. The pie chart (figure 12) below gives 
a clear indication of the wound management techniques that account to maximum share in 
terms of demand (revenue) and popularity. Hydrocolloid1 based products account for the 
largest sector of the United Kingdom Wound Management market, representing 33.8% of the 
market in value terms. Foams2 account for 27.4%, while Hydrogel Sheets3 have 10.6% of the 
market share. Amorphous Hydrogels4 is the smallest sector of the United Kingdom Wound 
Management market, representing 2.9% of the market in value terms.  
 
Figure 12: UK Wound Management Market, Source: Datamonitor, 2001 
4.2.3. Bio-Technology in Asia-Pacific 
The Asia-Pacific biotechnology market generated total revenues of $45.1 billion in 2008, 
representing a compound annual growth rate (CAGR) of 10.1% for the period spanning 2004-
2008. In comparison, the Americas and European markets grew with CAGRs of 13.8% and 
8.5%, respectively, over the same period, to reach respective values of $125.1 billion and 
$46.1 billion in 2008 (Datamonitor Report, 2009). Just as the case in China and UK, the 
medical/healthcare segment proved the most lucrative for the Asia-Pacific biotechnology 
market in 2008, generating total revenues of $29.1 billion, equivalent to 64.7% of the 
market's overall value. In comparison, the food and agriculture segment generated revenues 
of $12.5 billion in 2008, equating to 27.7% of the market's aggregate revenues (Datamonitor 
Report Biotechnology in Asia-Pac, 2009). 
                                                             
1
 These dressings mix with wound exudate to form a soft mass that allows for easy removal while 
protecting the wound from outside contamination from bacteria, fecal matter or urine. 
2
 Foam sheets are hydrophilic in nature, so can absorb a large amount of fluid, and provide a soft and 
cushioning layer for added patient comfort. They are easy for clinicians to apply and to remove, with 
minimal trauma to the patient and to the wound bed. 
3
 Hydrogels are useful for rehydrating sloughy or necrotic (dead) tissue and enhancing autolytic 
debridement. Patients like hydrogel sheets due to their cooling and soothing properties upon application.  
4
 Amorphous Hydrogels are useful for rehydrating sloughy or necrotic tissue and enhancing autolytic 
debridement. 
Gelatin based skin regenerating template: Market Research and Product Analysis 
 
 
Arjun G. Reddy   28 
 
 
 
Figure 13: Factors Influencing the Likelihood of New Entrants in the Biotechnology Market in Asia-
Pacific, 2008 
The likelihood of new entrants moving into the biotechnology market appears to be moderate 
based on the above figure for the Asia-Pacific market. Biotechnology start-ups are typically 
spin-off companies based on innovative products or processes resulting from discoveries in 
academic research. There is therefore a high degree of proprietary knowledge and products 
within the market, which restricts the entrance of new players. A 2009 Datamonitor Report 
on the Asia-Pac Biotechnology companies typically suggests that they have long start-up 
periods with little profit, combined with high fixed costs, and therefore must secure a high 
degree of venture capital backing. This may be difficult to obtain, given the long time before 
any return on investment is seen, and the relatively high risk that a start-up will not succeed 
in bringing a new product to the marketplace. Despite this, the report also suggest that a high 
level of growth of the biotechnology industry within Asia-Pacific, combined with a relative 
lack of restrictive government regulation of biotechnology operations compared to western 
regions is attracting significant biotechnology investment within the region. This is especially 
true of countries such as India and Singapore, which have a highly significant biotech sector. 
4.2.4. Bio Technology and Bio-Pharma in India 
The Pharmaceutical industry in India is fragmented with over 3,000 small/medium sized 
generic Pharma manufacturers. International pharmaceutical majors like Pfizer, Johnson & 
Johnson, Glaxo SmithKline and Novartis have an established presence in India. The Biotech 
Industry is seeing the emergence of several domestic private players with world-class 
capabilities. Major opportunities in Biotechnology are in the areas of Bio-informatics, 
Biopharma, Bio-agriculture and Bio-services. Many international biotech companies like 
Chiron Corp, GSK and Sigma Aldrich Corp have expressed interest especially in Bio-
manufacturing (Virtus Global Partners, 2008).  
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Department of Biotechnology (DBT) and the government of India have invested more than 
Rs.25 million to date in biotechnology. The biotech industry is one of the fastest growing 
sectors in India, with investment growing six-fold from 2000-2003 according to government 
sources. In 2005/06, the Indian biotechnology industry registered turnover of more than 
US$1.5 billion according to the DBT, with growth of 40%. By 2010, annual turnover is 
projected to reach US$10 billion (DBT Annual Report 2008-09). The figure below shows the 
Pharma sales of top 10 domestic companies. 
  
Figure 14: Pharma sales of top 10 domestic companies. Source: Cygnus Research, 2009 
4.3. Regulatory Environment 
Since Bio-Pharma falls under Biotechnology sector, a brief overview of the regulatory 
framework and government policies on Biotech Sector as a whole is analysed in this section. 
The regulatory framework in Biotechnology is undergoing a huge revamp and hence 
Biopharma sector is also expected to be affected by it. Though there are no specifically 
separate regulations and policies for the Biopharma sector, there are few aspects of the 
upcoming Biotech policy which will affect the Biopharma sector. 
4.3.1. Government of India Policy on Biotechnology 
The Department of Biotechnology (DBT) is the nodal agency for policy, promotion of R&D, 
international co-operation and manufacturing activities, which was set up in 1985. During the 
middle of 1980's, DBT focused on generating trained manpower and infrastructure 
development. 
The other government agencies involved in biotechnology R&D are 
- Indian Council of Medical Research (ICMR), 
- Indian Council of Agriculture Research (ICAR), 
- Council of Scientific and Industrial Research (CSIR) and 
- Department of Science and Technology (DST). 
 
In addition to the Central Government initiatives, several states have formulated their state 
specific biotech policies to boost the biotechnology sector in their respective states. Out of 
the six regulatory bodies in India (Appendix G), the most relevant one for the new skin 
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regenerating graft would be Drug Controller General of India, Ministry of Health - which is 
the official regulatory body governing manufacture and commercial release of 
pharmaceutical products, including recombinant products  
India's Intellectual Property regime is a dimension in facilitating collaborative activity, 
whether for drug discovery, clinical trials or for market-related trials. 
4.3.2. Funding Agencies in Biotech Research 
Institutional Framework 
At present, there are seven major agencies in India responsible for financing and supporting 
research in the realm of biotechnology apart from other sciences. They are: 
DST (Department of Science and Technology), DBT (Department of Biotechnology) and 
DSIR (Department of Scientific and Industrial Research) are part of the Ministry of Science 
and Technology; while ICMR (Indian Council of Medical Research) is with the Ministry of 
Health, ICAR (Indian Council of Agriculture Research) with the Ministry of Agriculture and 
UGC with the Ministry of Human Resource Development 
 
Figure 15: Institutional Framework and Public Sector Research Support.  
Source: Cygnus Research 
Foreign Direct Investments 
Foreign Direct Investment (FDI) is seen as a means to support domestic investment for 
achieving higher level of economic development through technology upgradation, access to 
global managerial skills and practices, optimum utilization of human and natural resources, 
making Indian industry internationally competitive, opening up of export markets and 
providing linkages and access to international quality goods and services. 
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Venture Capital funds 
With the increased role of established private sector as well as start-up companies investing 
in biotechnology, several financial institutions/agencies, both in public and private sectors, 
have launched venture capital (VC) funding mechanism. The Ministry of Science and 
Technology created these opportunities through the establishment of Technology 
Development Board (TDB) in September 1996 for providing financial assistance to industrial 
concerns and other agencies attempting development and commercialization of indigenous 
technology or adopting imported technology for wider domestic application 
(http://www.tdb.gov.in/). 
Banks continue to remain the major financing source for biotechnology in India with VC 
accounting for less than 20% of the funding (Cygnus Business Consulting & Research 2008). 
In 2003, the first national VC fund for biotechnology in India - The Biotechnology Venture 
Fund - was initiated. It was started with APIDCVCL, a joint venture between Dynam 
Ventureast Group and Andhra Pradesh Industrial Development Corporation (APIDC, 
Hyderabad, India). In 2004, it provided about INR 800 million (USD17.7m) in funding the 
biotech firms (www.apidc.org). Given the reluctance of existing venture capital funds to 
invest in early stage developments, APIDCVCL is targeting early stage tech businesses. 
4.3.3. National Biotech Development Strategy  
Government of India in 2005 came up with the National Biotech Policy Draft which talks 
about the future road map for biotechnology for a period of 10 years. Some of the Key policy 
recommendations & interventions in the area of biopharma mentioned in the national biotech 
policy draft are discussed below (National Biotech Development Strategy, 2007) 
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Regenerative Medicine: 
The first wave of real healthy life extension therapies seems likely to result from research 
stem cells and regenerative medicine which helps natural healing processes to work faster, or 
uses special materials to re-grow missing or damaged tissues. Doctors use regenerative 
medicine to speed up healing, and to help heal injuries that cannot heal on their own. 
Regenerative therapies have been demonstrated (in trials or the laboratory) to heal broken 
bones, bad burns, blindness, deafness, heart damage, nerve damage, Parkinson's and other 
conditions. Regenerative medicine will result in an extended healthy lifespan; which will 
repair the damage caused by ageing, organ by organ. 
Bioengineering: 
Bioengineering covers a wide range of areas such as tissue engineering, biomaterials for 
therapeutics, biomedical devices and instrumentation, biomedical sensors etc. Research is 
focused on developing non-immunogenic materials to serve as scaffolds for regeneration of 
damaged tissue. Bone and cartilage can be grown today while there is potential for other 
tissues too.  
The current market for medicinal devices such as implantables, disposables wound care, 
dental and orthopaedic materials etc is estimated at around INR 70 billion and another INR 
50 billion for the medical instrumentation sector in the country, with a growth rate of 15% 
per year (Cygnus Business Consulting & Research 2008). Nearly 80% of this demand is met 
by imports.  
4.4. Clinical Trials Market in India 
Contract research involves outsourcing of various activities relating to R&D to Indian 
pharmaceutical companies by global companies. Contract research includes both drug 
discovery research and clinical research. According to a report given by McKinsey, clinical 
trials comprise 65% of the contract research market and new drug discovery makes up 
remaining 35%.  
The new skin regenerative graft or any other bio pharma product has to undergo clinical trials 
before entering the market. The different phases are mentioned in the figure starting from 
Drug discovery and all the way to Post marketing testing. Clinical trial is the final step in 
drug development process after preliminary laboratory research and animal testing. Some of 
the questions considered during this research were- Is India the best place to conduct clinical 
trials for this new product? If yes, what are the advantages and disadvantages?  
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Figure 16: Phases in drug development process. Source: ³&OLQLFDO7ULDOV,QGXVWU\LQ,QGLD´)HEUXDU\2008 
,QGLSHGLD³&OLQLFDO7ULDOV´0\HORPD&DQDGD³FOLQLFDOWULDO)$4V³ 
 
Figure 17: % distribution of clinical trial phases, 
Source: RNCOS 
If we have to weigh the pros and cons of conducting clinical trials in India then few key 
observations are as follows: 
Cost Effectiveness: 
India offers significant cost savings in clinical trials. Multinational pharmaceutical companies 
can achieve cost savings of around 30±50% when outsourcing clinical trial projects to India 
(Companies and Markets Research, 2009). In the US, it might take nearly three years to get 
around 100 patients to conduct trials on them, in India the same number could be gathered in 
about six months. 
In 2008, there was an increase in 
clinical trials by 143% from 2007. 
Among the total number of 
clinical trials conducted in the 
year 2008, 65% of them were in 
phase 3. This indicated the time 
taken for FDA review and 
approvals would take the 
maximum amount of time. On the 
contrary, phase 1 has the least 
time delay with just 2% (fig 17). 
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Figure 18: India ± Cost competitiveness. Source: Companies and markets Research, 2009 
Sound Healthcare Infrastructure: 
 
Table 6: Sound Medical Infrastructure.  
Source: (Indian Panacea, 2006) 
Despite the above advantages from clinical trials in India, there are few glaring disadvantages 
that could hamper the growth in this sector. 
Shortage of Research Professionals and lack of data exclusivity: 
 
Figure 19: Mismatch in Demand and supply 
. Source: AceIndia 
The Indian law has no statutory protection for the data that is submitted to regulatory 
authorities for testing for approval of any manner of products. Although India is a signatory 
to the TRIPS5 Agreement, no new provisions of law have been introduced to protect test data. 
The existing legal provisions are inadequate and compensation-focused. The requirements of 
data protection and exclusivity obligations are proactive in nature, i.e. focused on preventive 
                                                             
5
 Trade Related Aspects of Intellectual Property 
India has established world-class expertise 
in complex medical practices such as 
cardiac care, cosmetic surgery, joint 
replacements, neurosurgery, ophthalmology 
and dentistry at par with the best hospitals in 
US and UK. They offer huge array of tailor-
made options such as private room, 
translator and private chef. All medical 
investigations are conducted using the latest, 
technologically advanced and cutting edge 
diagnostic equipment. Indian 
pharmaceuticals meet the stringent 
requirements of FDA. Table 6 is a snapshot 
RI ,QGLD¶V KHDOWKFDUH LQIUDVWUXFWXUH (Indian 
India is facing a shortage of Good 
Clinical Practice (GCP) certified sites 
and investigators (figure 20). Over the 
next five years about 1,500-2,000 
good clinical practices (GCP) trained 
investigators supported by 50,000 
clinical research professionals would 
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mechanisms. There is no legislation corresponding to the "Hatch Waxman Act6" (Jaya 
Bhatnagar, 2009). 
Delays in trial approval and challenges of unethical trials: 
Delays in granting approvals are affecting pharmaceutical companies and CRO7s in India. 
Delays happens as the Drugs Controller's office depends on external experts and agencies 
such as Indian Council of Medical Research for advice and additional permissions required 
for import of trial samples and export of samples to foreign laboratories (Thaindia, 2008). 
 
Figure 20: CT approval time in India  
Source: thaindia 
The clinical trial business is dependent upon a large pool of human subjects - or, a stable of 
human guinea pigs - in who the drugs are tested. But with increased awareness of the risks 
involved in testing drugs under development, the pool of human volunteers in industrialized 
countries has shrunk. The drug industry is looking for alternatives to carry forth the much 
need trials. Therefore they are increasingly moving to underdeveloped countries where they 
are enrolling uninformed, non-consenting people who have few choices in life. 
Unfortunately, India is a target drug testing population. A spate of unfortunate events over the 
past few years has brought to the fore the rampant practice of conducting unethical and even 
illegal clinical trials (Clinical Research 2008).  
Supreme Court of India had hauled up two top biotech companies Shanta Biotech & Biocon 
for openly conducting illegal clinical trials of new drugs on unsuspecting patients after a 
litigation filed by Aadar Destitute and Old People's Home (an NGO). NGO alleged that the 
two companies had conducted improper clinical trials of Streptokinase - a new clot-busting 
drug used in heart attacks without requisite permissions, as a consequence eight people lost 
their lives (Asia Times, 2004). 
 
                                                             
6
 In 1984 the US became the first country to enact data exclusivity legislation. The Drug Price Competition and Patent Term 
Restoration Act, commonly known as the "Hatch-Waxman Act", actually relaxed the level of protection afforded to testing 
data in the US. Under the Hatch-Waxman Act, applications for approval of new drugs receive 5 years of data exclusivity. 
Applications for the approval of new indications for an existing drug receive 3 years of data exclusivity. 
7
 Contract Research Organisation 
³,QGLD WDNHV D PLQLPXP RI HLJKW PRQWKV WR
accord clinical trials approvals whereas in 
Canada, the UK, and the US, clinical trials 
DSSURYDODUHJLYHQLQDPRQWK¶VWLPH´ The 
Associated Chambers of Commerce and 
Industry of India (ASSCHAM) senior vice-
president Swati Piramal said 
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4.5. Skin Regenerating Grafts for Burns and Wounds 
4.5.1. Background 
The outermost layer of the skin is called epidermis. The cells involved here are called 
keratenocytes. If the top layer is destroyed it can be easily regenerated. The layer below is a 
thicker layer called Dermis. The cells involved here are called fibroblasts. Majority of the 
products that are currently available in the market are aimed at healing damaged dermis layer 
of the skin. 
 
Figure 21: Cross Section of Human Skin. Source: infovisual.info 
During the healing process the major challenge is to prevent infections from occurring. On 
VXFFHVVIXOO\ GRLQJ WKLV ³ RI WKH EDWWOH LV ZRQ´ VD\V 'U $VKRN .XPDU 'UHVVLQJV, 
including normal band aid, could be classified under this segment. The different types of 
burns characteristics could be defined as follows (www.burnsurvivor.com): 
1st Degree burns: Involves top layer of skin and hair, redness, swelling. It may peel, generally 
heals in 3-5 days. There is no scaring and may cause itching while healing. 
2nd Degree burns: Involves skin and hair, plus deeper skin layer (dermis), sweat glands, and 
hair follicles. It results in blistering, redness, area turns pale when pressure is applied, red 
color returns slowly. 
3rd Degree burns: Involves all thickness of outer skin including fatty layer. Looks dry or 
leathery, may be charred. There is little or no pain (nerve endings have been damaged), 
Greater possibility of infection, since blood supply to area is damaged. This results in 
scarring post healing. 
Skin regenerative template/grafts/tissue engineered scaffolds main purpose is to allow the 
cells to grow and the wound dressing prevents any infections form taking place during the 
healing process. For assisting this regeneration of cell in the affected area a scaffold is used. 
Generally they are 2mm to 4mm in thickness. 
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4.5.2. Products in the Market ± An Overview 
The field of skin substitutes has been bombarded with almost Messianic zeal in an effort to 
develop the next generation of newer and better skin replacements. These dressings are made 
with varied combinations of synthetic and/or biologic substances. Although all may have 
some utility and each has its champions, they appear to find more application in the larger 
and therefore more lucrative wound market. Few of the popular companies in the market who 
make products which are used for treating 2nd degree burns and wounds are mentioned in 
table below. This research is focused on burn products which are scaffold based. 
Name Description  Website 
 
Innovative Tissue Engineering 
for wound closure, corneal 
transplants, and adult stem cell 
therapy in cosmetic surgery and 
other clinical indications  
www.invitrx.com  
 
Helicoll is a Type-I collagen 
sheet used for treating 1st and 
2nd degree burns and wound 
dressing  
www.encoll.ocm 
 
AlloDerm®: Regenerative 
Tissue Matrix: improving 
functional outcomes and 
cosmoses in grafting procedures  
www.lifecell.com  
 
,QWHJUD%LOD\HU0DWUL[
Wound Dressing for partial and 
full-thickness soft tissue trauma 
and chronic wounds 
www.integra-ls.com  
 
Neuskin-FLVDQHIIHFWLYH
epidermal substitute that 
supports epidermal cell 
attachment and migration  
www.medira.co.uk  
 
A comparative study was done to understand the characteristic features of these collagen 
based products and how they differ from one another. The results of the study and a broad 
overview are mentioned below: 
Type Characteristics Drawbacks 
,QWHJUD x Single layer of Glycosaminoglycan and a covering 
semi-permeable polysiloxane (silicone layer) 
x Exceptional Strength and flexibility 
x Room temperature storage and long shelf life 
x Provides excellent coverage over exposed bone, 
tendon, cartilage and joints. Of 166 instances of 
exposed internal structures that are ordinarily 
closed with flaps, Integra closed 90% of them 
(Jennifer Furman, 2004) 
x Very Expensive 
x Not used globally 
x Extreme care must be 
considered during 
packaging and 
transportation (Total 
Recall 2009) 
Neuskin-) 
 
x Collagen dressing derived from Piscean sources: 
Biocompatible as per EN ISO 10093 standards. 
Non-toxic, non-allergenic, non-immunogenic, non-
x Avoid in patients 
hypersensitive to fish 
products. Chances of 
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pyrogenic (Gottlieb, 2004) 
x Transparent membrane enables wound 
visualization. Reduces wound pH, infection and 
fluid loss (Hampton S, 2008) 
x Epidermal substitute for scald burns, superficial 
partial thickness burns (IIA) and mixed burns 
Storage: Dry place at temp < 25ºC. It is sterilized by 
irradiation with 3yrs shelf life (Kilinc, 2001). 
Irritation and Infection. 
The remedy for this is to 
either discontinue or 
control with systematic 
antibiotics respectively 
(Shukla VK 2007) 
+HOL&ROO 
 
x Type-I Collagen sheet with transparent membrane 
enables wound visualization 
x Does not require excessive washing to remove 
preservatives. Can be used with just 2 to 3 min of 
soaking in sterile water. 
x Reduces wound pain while accelerating tissue 
remodeling without causing irritation 
x Helicoll reduces the repeated dressings, hospital 
stay and has been shown to reduce the overall 
wound treatment cost by over 40% (Advanced-
Biotech, 2009). 
x Not advisable for 
patients hypersensitive 
to bovine products. 
x Non adherent secondary 
dressing is required to 
maintain moist wound 
environment.  
x Helicoll may form a 
caramel coloured gel, 
which can be rinsed 
away with gentle 
irrigation. 
x Can be used only for 1st 
and 2nd degree burns 
trauma with skin loss, 
chronic skin ulcers Skin 
donor sites 
4.5.3. Existing Cutting edge technology in India for treating burns 
 ³Artificial Skin´E\1DWLRQDO,QVWLWXWHRI,PPXQRORJ\ (NII), New Delhi:  
1,,KDYHGHYHORSHGDQRYHO³VXUIDFWDQWPHGLDWHG IXVLRQSURFHVV´UHVXOWLQJ LQVHOI-assembly 
of polylactide particles into membrane like structures at room temperature named as ARTSK-
NII. These are made from FDA approved biodegradable polymer extensively used in 
biomedical application and are nontoxic and highly biocompatible. The process is simple and 
can be carried out in room temperature without using any expensive or complicated 
instruments and refrigeration. In experimental animal wound models, the polylactide 
membranes showed faster wound closure with increased strength of the healed skin over 
currently used polylactide composite membrane. Once proven in animal/human model, this is 
expected to provide a cheap way of producing artificial skin for burn and wound treatment. 
NII team has bagged the Second prize at Intel-UC Berkeley Technology Entrepreneurship 
award in Nov.2008 in U.S.A for the innovation (www.nii.res.in/). 
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4.6. S.W.O.T of the Bio-Pharma industry 
Strength 
Potentially a huge market 
The sector analysis in the previous section clearly indicates a great potential in the Bio-
Pharma market. If the new gelatin based product goes through the clinical stages successfully 
then tapping this market would definitely mean year on year profits. 
Weakness 
Low per-capita expenditure 
A study by the Indian Commission on Health in India (2009) indicated that 56% of Indian 
health expenditure is on drugs, equivalent to around US$17.9 billion in 2004, but much of 
this is on traditional Indian remedies rather than allopathic drugs. A large proportion of 
pharmaceutical expenditure is tax, which is equivalent to around 30-35% of the total 
according to the OPPI, taking into account customs duty, excise, sales and other taxes. 
Concerns remain that the presence of fakes or substandard medicines in India is alarmingly 
high. Despite the efforts of large companies to protect their products, such as the use of 
holograms, counterfeit drugs remain a problem. The market for these drugs is estimated to be 
as high as 15-RI,QGLD¶VWRWDOSKDUPDFHXWLFDOPDUNHW(VSLFRP 
Problems with some contract research organisations not adhering to international GCP/ 
GLP standards when undertaking bioequivalence studies (discussed in sec 4.4) 
Opportunities  
Mergers 
0HUJHUV SURYLGH RSSRUWXQLWLHV VXFK DV HQWHULQJ QHZ PDUNHWV H[SDQG WKH JURXS¶V FRUe 
FDSDELOLWLHV HQKDQFH PDUNHW VKDUH DQG EULQJ QHZ SURGXFWV XQGHU WKH JURXS¶V SURGXFW
portfolio which could enables strong growth prospects for the new skin regenerative product. 
International companies are showing great interest in entering India via alliance with Indian 
Pharma companies. 
GSK announces a strategic alliance with Dr. Reddy's Laboratories Ltd -  GlaxoSmithKline 
plc (GSK) has announced an agreement with Dr. Reddy's Laboratories Ltd (Dr.Reddy's) to 
develop and market selected products across an extensive number of emerging markets, 
excluding India. This is another significant step forward in strategy to grow and diversify 
GSK's business in emerging markets. Growth in both population and economic prosperity is 
leading to increased demand for branded pharmaceuticals. This new alliance will combine 
'U5HGG\
VSRUWIROLRRITXDOLW\EUDQGHGSKDUPDFHXWLFDOVWRJHWKHUZLWK*6.¶VH[WHQVLYHVDOHV
and marketing capabilities (Pharmaceutical Business Review, 2009). 
Perfect competition among Collagen based products 
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As mentioned in the previous sections the products that are currently there in the market for 
skin regeneration are all collagen based products. These products are very expensive and thus 
there is a price war among these products. Any new product in the market which performs 
similar tasks and activities and at much affordable price could have a superior advantage in 
the Wound and Skin care management industry. There could be a potential First Mover 
Advantage for that product. 
Government Initiatives 
The Karnataka government announced its plan for a revised Millennium Biotech Policy at the 
Bangalore Bio 2009 by Karnataka Chief Minister, B S Yeddyurappa. The revamped biotech 
policy aims at bridging academia with the industry. The State government is committed to 
providing an industry-friendly and business-friendly environment for the growth and 
development of knowledge-based industries. 
Another initiative of the government is to develop a biotech cluster in Bangalore, which is 
phase-II of the expansion of the biotech park in Electronic city on Hosur road. The project, to 
be built on a public-private partnership model, will involve Rs 300 crore investment. The 
state will contribute 60 acres worth Rs 100 crore and the remaining investment is expected to 
come from private players. 
The state government commissioned a Rs 16 crore R&D and institutional block comprising 
of IBAB (Institute of Bioinformatics & Applied Biotechnology) and CHG (Centre for Human 
Genetics) at the biotech park in February, 2009. The government of India, recognising IBAB 
as a centre of excellence, has given approval for setting up the Rs 34 crore Bio-IT centre 
there. 
Threat 
Regulations related to animal-derived products: 
Certain products such as dermal regeneration products, biomaterial products for the spine, 
nerve and tendon repair products among others, contain materials derived from animal 
sources, are increasingly subject to scrutiny in the media and by regulatory authorities. This 
public scrutiny has been particularly acute in Japan and Western Europe with respect to 
products derived from animal sources, because of concern that materials infected with the 
agent that causes bovine spongiform encephalopathy, otherwise known as BSE or mad cow 
disease, may, if ingested or implanted, cause a variant of the human Creutzfeldt-Jakob 
Disease, an ultimately fatal disease with no known cure. 
Certain countries, such as China, Taiwan and Argentina, have issued regulations that require 
its collagen products be processed from bovine tendon sourced from countries where no cases 
of BSE have occurred. Similarly, the EU has requested that its dural replacement products be 
sourced from bovine tendon sourced from a country where no cases of BSE have occurred or 
classified by European Standards as Class IV material (Integra Live Science Cooperation, 
2007). In addition, among other regulations, Japan requires that the tendon used in the 
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manufacture of medical devices sold in Japan originate in a country that has never had a case 
of BSE.  
Currently, companies like Integra purchases its tendon from the US and New Zealand 
(Cetification Requirements USDA, 2008). If Integra cannot continue to use or qualify a 
source of tendon from New Zealand or another country that has never had a case of BSE, the 
company will not be permitted to sell its collagen haemostatic agents and products for oral 
surgery in many countries. Ban of such products, could have a material adverse effect on any 
FRPSDQ\¶VEXVLQHVV 
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Chapter 5: Product Analysis 
As a part of the science bridge initiative, the skin regenerative graft that is being developed 
for addressing not just burns (second or third degree burn) and wound injuries but also to 
treat diabetic ulcers (deep wounds). This tissue engineered product is particularly designed to 
handle complications that arise from autograft treatment (traditional procedure) and with the 
aim to be economically affordable by majority of people in developing countries. The 
information articulated in this chapter is mainly from the data gathered during interviews and 
field visits. 
5.1. Current Situation 
Collagen is a protein that is derived from Bovine (animal sources). This helps the dermal 
cells to grow during skin regeneration. The scaffold used currently in the market come with 
the combination of antibodies and thus as a single layer. Silver is commonly used as an 
antibody. These scaffolds come with a coating of fibrinogen (Bio active molecule) that assists 
the development of blood vessels and not just the dermal cells. 
Despite the high percentage usage of these kinds of products in the UK market as well as 
Indian market, there are a couple technical drawbacks that are equally accepted among 
patients and doctors.  
³These products take a lot of time for healing. The regeneration is very slow as there 
is no 100% protection offered to prevent infection Therefore the fibroblasts develop 
into the next state which is the miofibroblasts, which appears as a shiny surface...´
says Dr Ashok Kumar 
The slow regeneration is due to the infection which in turn is due to the shortage of 
antibacterial agent. To further elaborate, an ideal scaffold for this purpose should have very 
good degradable properties. Collagen, which is the main ingredient of the scaffold acts as a 
good degradable substance that is best suited for the purpose. However, most of the collagen 
products in the market are mixed with the antibacterial agent (mostly silver) to form a single 
layer. Therefore the degradation of both the substances happens in parallel exposing the 
wound to infection. This technical drawback results in the development of a scar post 
treatment.  
Secondly, it is important that the scaffolds have good absorption capacity as the wounds have 
lot of exudes. The burn surgeons who were interviewed in Bangalore believe that having a 
good absorption capacity is a vital characteristic in such products. They also said that most of 
these internationally available products are not very popular in India mainly because of the 
cost factor.  
³7KHVH SURGXFWV DUH ZD\ WRR H[SHQVLYH WR EH ERXJKW E\ SDWLHQWV YLVLWLQJ WKH
JRYHUQPHQWKRVSLWDOV´says Dr. Vasunetra, Bangalore Medical College. 
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And when the surgeons from the private hospitals were interviewed, they had similar answers 
that pointed out to the heavy pricing of the product. It is evident by looking at the burns 
statistics in India (appendix) and the UK (appendix) that the demand for products to treat 2nd 
and 3rd degree burns and wounds is increasing. 
5.2. The Process 
Based on the qualitative research done by interviewing Burns department surgeons in 
Bangalore, Nottingham and Sheffield the process followed currently in India and UK for 
treating burns and wound are discussed below. 
Victoria Nursing Home, Bangalore (Specialty burns center government hospital): 
Burns on a patient are first classified as less than 20% or greater than 20% depending on the 
location of the burn on the body. The later is an elaborate process involving IV fluids which 
DUHLQMHFWHGLQWRWKHSDWLHQW¶VERG\WRUHJDLQWKHORVWERG\IOXLGVAfter the burn, for the next 3 
to 4 days the patient is treated with various antibiotics and painkillers. An ointment 
(Neosporin) is used if the area of burn is facial and drugs like Deriphylline, Hydrocortisone 
and Budacort Nebulization are used in case of respiratory burns. Finally, around day 4/6 a 
dressing using either Kollagen or calgigraft is done.  
However if the burns are less than 20% the patient is treated with just ointment of Silver 
Sulfadiozine and anitibiotics like ciptofloxocine and painkillers are prescribed.  
 
Figure 22: Process followed in treating 2nd and 3rd burns in Vitoria Nursing Home, Bangalore 
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Clinical Sequence for treating wounds: 
It was found that majority of the hospitals in India followed the above procedure to treat 
burns/wounds. Among the commercially available products, the most commonly used 
product in India is Kollagen and the next most popular product is Hellicol. However, in the 
US, UK and other European countries advance dermal regeneration products are being used 
to treat burns and wounds. The clinical process of treatment using these products would 
approximately take 30 days for wound closure. In approximately 14 to 21 days, the scaffold 
LV HYHQWXDOO\ UHPRGHOHG DV WKH SDWLHQW¶V FHOOV UHEXLOG WKH GDPDJHG VLWH &RPSOHWH ZRXQG
closure occurs as epidermal cells migrate from the wound edges. The clinical sequence for 
treating wound is presented in the below flow chart. For large wound, a layer of epidermis 
may be applied to the wound area to facilitate complete wound closure. 
 
Figure 23: Clinical sequence for treating burns or wounds using regenerative skin grafts 
 
DAY 0: PRE-
TREATMENT
Accurate diagnosis: There must be thorough pre-operative control of inflammation,
ulceration, debris and bioburden, and edema (as best as the disease and available
treatments permit)
DAY 1: 
DEBRIDEM
E-NT
Preparing the wound bed free from debris and necrotic tissue: Before
placing any wound dressing the existing wound must be completely
excised or surgically debrided to ensure the wound bed and edges contain
viable tissue
DAY 1: 
APPLICATI
ON
Wound dressing products, for Ex: ,17(*5$ Matrix Wound Dressing, Algicel,
AlloDerm® etc, are applied on the excised wound bed.
Fluids invade the matix within minutes of application, adhering it to the wound. It can be
affixed with sutures, staples, or any suitable alternative dressing.
DAY 7-14: 
CELLULAR 
INVASION and 
CAPILLARY 
GROWTH
Cell migration into the matrix begins and a new vascular network is establised. The
scaffold is eventually remodeled as the patient's cells rebuild the damaged site. When
using either the regenerative Matrix or Bilayer Matrix dressings, most of the collagen
templates are biodegradble and is absorbed into the body.
DAY 21-
56+: 
WOUND 
CLOSURE
Epidermal cells migrate from the wound edges to complete wound closure. For larger
wounds, a thin epidermal autograft may be considered to facilitate wound closure. A
thin 0.004 ± 0.006 in. (0.1016 - 0.1524 mm) epidermal autograft may be applied over
the new remodeled skin.
Epidermal coverage over the wound yields a permanant and lasting wound closure.
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5.3. The working environment 
As the science of wound care advances, the new product developed in the labs of IIT Kanpur 
biosciences department provides caregivers with alternatives that deliver wound dressings 
offering superior performance at very lower cost. These dressings are a new and unique line 
of dressings. These dressings can be thought of as "all-in-one' dressings for effective wound 
bed preparation.  
The new µcryogel sheet¶ - skin regenerating graft dressings is a bi-layered dressing with a 
combination of a degenerative layer which comes in contact with the wound and an 
antibacterial layer. The bottom layer is similar to Integra, however the scaffold here is made 
of gelatin derived from fish source.  
³Collagen is a polymeric chain and gelatin is the hydrolyzed part of the chain. This 
material made of similar amino acids that recognizes the cells. Also, gelatin is almost 
10 times less expensive than collagen´ ± Dr Ashok Kumar. 
Therefore the new product promises cost effective product with high acceptability in the 
market. The unique multilayer design provides a wound dressing that is easy to apply with 
high degree of flexibility in terms of application.  
Regenerating template 
The Regenerative Layer is the bottom layer which comes in contact with the wound and is 
brittle by nature when unpacked. However, before its application on the burn/wound, it is 
dipped in water. This changes the properties of the material and makes it strong and flexible. 
The main composition of this material is gelatin and fibrinogen (for angiogenesis8). This 
dressing is designed for placing directly on the wound. The dressing can be left in place for 
up to 3 weeks depending on the amount of burn/wound drainage. This layer dressing is 
composed of specially formulated cryogel sheets that are extremely flexible, minimally 
adhering and delivers superior absorption capabilities (capillary action). This Cryogelation 
technology is patented to IIT Kanpur. The cryogel sheet has a smooth bottom surface (which 
comes in contact with the wound) and the upper rough surface. The antimicrobial layer will 
be placed on this layer and it is 100% covered, uniformly and circumferentially 
approximately with a thickness of 2mm thickness.  
This dressing is extremely versatile and user friendly, they seem to conform to hard-to-dress 
areas and providing mild compression when needed. Wound Contact Dressing are indicated 
for management of incisions, skin grafts, donor sites, lacerations, abrasions, pressure sores, 
chronic wounds, chronic ulcers, dermal ulcers, vascular ulcers, and diabetic ulcers. These 
dressings can be thought of as "all-in-one' dressings for effective wound bed preparation. 
Key Characteristics: 
ͻ Provides immediate wound coverage 
                                                             
8
 The process of creation of blood vessels 
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ͻ Highly conformable for various anatomical sites 
ͻ Excellent performance in deep donor sites as it can be applied as multiple layers. 
ͻ Exceptional strength and flexibility 
ͻ Room temperature storage 
ͻ Long shelf life 
ͻ Can be used separately without the dressing template covering it. 
Dressing template ± Antimicrobial layer 
The top layer provides a topical antimicrobial barrier that reduces the bacteria and fungi 
counts on the wound surface and within 2 to 4 millimeters of the wound surface and also 
from the external environment. The dressing material is made of Polyvinyl pyrolidone (PVP) 
cross linked with polyethylene glycol diacrylate (PEG ± Da). Lab experiments has shown to 
have powerful and long-lasting antimicrobial activity.  
³7KH UDWH of diffusion into the regenerative template would go on for minimum 2 
months period..´says Dr. Ashok kumar 
The biocompatible PVP releases the antibodies (Iodine) in a controlled manner- similar to 
that of ionic silver (used by few products in the market in this segment) - but without the 
associated toxicity of ionic silver. PVP exists as a liquid form however, IIT Kanpur have 
developed a procedure to make it into a ³non-degenerative sheet´ format of varied 
dimensions.  
Key Characteristics: 
x Has very high tear strength 
x Could be used separately as a dressing material 
x Controls water vapour loss 
x Long shelf life (2 years) and can be stored under room temperature 
 
Going that extra mile 
There is a parallel research that is being carried out in IIT Kanpur where the focus is on 
developing a product with µZRXQGDHVWKHWLFORRN¶. After three weeks of regeneration of the 
dermis skin the team is working on putting a layer of keratinocytes9 on the top of the newly 
developed dermis by removing the dressing covering this layer. The keratinocyte layer is a 
tissue cultured cell sheet which is cyopreserved (Low temperature preservations) in the 
hospitals. They claim that this would result in regeneration of original skin!  
³7KHVHVWHPFHOOVZRXOGLQFUHDVHWKHFRVWVE\-IROGV´says Dr Ashok kumar 
Since this procedure involves high costs the target market is mainly the developed countries 
like U.S and UK. 
                                                             
9
 Keratinocytes are stratified, squamous, epithelial cells that comprise skin and mucosa (AAD, 2009) 
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5.4. Operational Plan 
Raw-materials 
The current operational environment is only under lab conditions. Therefore the raw material 
requirement and usage is scaled down to a great extent when compare to the mass scale 
production in the factories. For the regenerative layer the raw-material used is just gelatin 
derived from Piscean source. For the dressing material the rawmaterials used are Iodine, 
Polyvinyl pyrolidone (PVP), and polyethylene glycol diacrylate (PEG ± Da). 
Suppliers 
Irrespective of the lab environment or at a commercial scale, a typical supplier for 
manufacturing of this kind of product would be a Life Science and High Technology 
company whose biochemical and organic chemical suppliers cater to the scientific and 
genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and 
chemical manufacturing. In the labs of IIT Kanpur, the rawmaterials are procured from one 
such leading life science supplier called Sigma-Aldrich.  
Address: Plot # 12, Bommasandra Jigani Link Road, Bangalore - 560 100 
Phone: +91-80-6621 9400 
Fax: +91-80-6621 9450 
email:india@sial.com 
Web: http://www.sigmaaldrich.com 
 
An Ethylene Oxide Sterilizers and a cryostat are the main machinery needed for the 
manufacturing of this product. The supplies for sterilizers could be firms like Kaustubh 
Enterprises, Rujikon (www.indiamart.com/kaustubh/) and for cryostats it could be companies 
like Sipcon Instruments Industries (www.sipconinstrument.com/cryostat.html). 
Manufacturing: 
Since the technology involved in the manufacturing of these materials is very simple, the cost 
involved in setting up the machinery is low. The patented manufacturing technique followed 
for producing the regenerative template is called Cryogelation technique. The dry solid sheet 
of gelatin is sterilized by using Ethylene Oxide Sterilize. For manufacturing the dressing 
material, the cryostat is used. A special technique that is unique to IIT Kanpur is adopted to 
convert the liquid raw materials into solid sheets of 2mm thickness that could be later placed 
over the wound/burn as a dressing. 
Packaging: 
The product would be available in the market in three different probable formats. The 
regenerative template and the dressing template would be available separately in two 
different packages; alternatively they would also be available packaged as one unit. The 
regenerative template will be dry and sterilized before packing. The dressing template is also 
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dry during packaging, however it is not sterilized. Both the templates could be stored in dry 
temperature with a very long shelf life. 
5.5. Financial Information  
The impact of Budget 2009-10 on Bio-pharmaceutical industry has been quite positive. 
Custom duty on Advance Medical Equipment has been reduced, so the cost of new advanced 
plant in the research and manufacturing sector will come down. The 150% of weighted 
deduction on in-house research has been for all the manufacturing business being extended 
except for a small negative list. In the budget, Rs20.57 billion is allocated for healthcare 
sector to strengthen the PHC and to increase the operation of 24×7 facilities.  
Despite the positives there are few negative effects as well: central excise duty has been 
increased from 4% to 8%, which will reduce the margins of the manufactures. Even 
Minimum Alternative Tax (MAT) has been increased from 10% to 15% and has increased 
from seven to 10 years (Ministry of Finance - Govt. of India, 2009). The budget seems like 
the excise duty cut and other proposals may help the common person but not the company. 
In spite of the early stages of the new product life cycle, a cost estimate was done by 
considering the industry standard cost structure as the benchmark. The figure below gives a 
breakdown of various parameters that contribute of the final pricing of the bio-pharma 
product. 
 
Figure 24: Cost Structure as percentage of net sales. Source: BSE India, Cygnus Research 
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Table 6: Comparative cost structure between 2008 and 2009 . Source: Cygnus Research 
5.5.1. Extrapolation from the financial data 
To extrapolate the approximate price of the product in the make, firstly, the costs were noted. 
The machine costs are only one time investment. Besides, if it is a well established 
Pharmaceutical/biotechnology company then these costs could be canceled.  The reason 
being, sterilizers and cryostats are widely used in such companies for other purposes.  
Cost of Cryostat ± approx Rs. 3,00,000 (www.sipconinstrument.com/cryostat.html)  
Cost of sterilizer ± approx Rs. 5,00,000 (www.indiamart.com/kaustubh/)  
The above costs of equipment is only for small scale manufacturing (in the lab condition) 
Cost of Raw material used: 
Gelatin from fish skin ± 500gm costs Rs 2,780 (product #G7041-500G from 
www.sigmaaldrich.com)  
In comparison, Collagen from bovine Achilles tendon ± 25gm costs Rs 19,100 (product 
#C9897-25G from www.sigmaaldrich.com) 
Similarly, form the same firm, Iodine of 100gm costs around Rs 610, PVP of 1 Kg costs 
around Rs. 3000 and PEG of 500ml costs Rs. 5000.  
Calculations: 
a) Regenerative Template 
2gms of gelatin is required to produce a 10X10 cm sheet of regenerative graft (IIT Kanpur 
Research Team).  
 
Therefore for 500gms ± 250 sheets ± approx Rs.3000 
For 1 sheet it would cost 3000/250 = Rs 12/sheet (Raw material costs only) 
b) Dressing Template 
For 2000 sheets of 10X10 the raw material required are  
Iodine (100gm) Rs 610 + PVP (1Kg) Rs 3000 + PEG (500ml) Rs 5000 = Rs 8610 (IIT 
Kanpur Research Team). 
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Therefore for 1 sheet the cost would be 8610/2000 = Rs 4.3/sheet 
The total cost of a 10X10 cm sheet of regenerative layer and the dressing template would cost 
12 + 4.3 = 16.3 ~ Rs. 17 
By taking the data in the previous section on cost structure as a percentage of sales, the 
multiplying factor could be found out. If 42.84% is the industry standard for percentage of 
raw material, then the derived multiplying factor is 0.396. By using this value the remaining 
parameter that account to the final price of the product can be extrapolated. For ex: µOther 
expenses¶ would account to 0.396 X 24.87 = Rs. 9.84 
Similarly, after calculating the costs for all the other parameters, the summation of these costs 
would account to the final price of a 10 X 10cm (or %fX %f) size regenerative template as well 
as the dressing material. Therefore, after all calculations the total price of this gelatin based 
product would be around Rs. 38 (including tax). For a box of 10 sheets it would cost around 
Rs. 400 only! (or $10) 
5.5.2. Pricing Power 
The products in the market for wound management like the skin regenerating graft are ideally 
packaged in either a box of 5 or 10. The size of one sheet varies from company to company. 
The price breakdown of few competitors products are mentioned in the table below. To ease 
the comparison, the cost of the product for a dimension of 5" X 5" or 10cm X 10cm is also 
mentioned. It is very clear by the comparison that the new product is extremely cost effective 
and could very well have a monopoly in the sector. 
Product Name Pricing  Source 
3URPRJUDQ0DWUL['UHVVLQJ
(Johnson & Johnson) 
4.3" x 4.3" is $17. Therefore a 
5" x 5" would cost around $22  
www.allegromedical.com 
ADAPTIC Non-adhering 
Dressing (Johnson & Johnson) 
3" X 3" is $2.15. Therefore, a 5" 
X 5" would be around $5 
www.allegromedical.com 
Aquacel® Hydrofiber® Pad 4" X 4" 10/Box costs $138.46. 
So, , a 5" X 5" would be around 
$21 
www.betterlivingnow.com 
Biobrane® Biosynthetic wound 
dressing 
5/Box pad EA 5" X 5" costs 
$319.50. Therefore one  5" X 5" 
sheet is $32 
www.betterlivingnow.com 
&HOOHUDWH5;$FWLYDWHG
Collagen Gel 
1 each (28 gm) is $63 www.betterlivingnow.com 
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Chapter 6: Discussion 
The global Biotechnology market clearly indicates that it is very lucrative as it contributes to 
the generation of 21.27% of world's Phrama revenues. China and India have emerged in the 
top 5 markets growing big and fast. Furthermore, the Bio-Pharma industry accounts to almost 
75.24% of the biotech industry making it the most attractive market to carry out R & D. India 
has become an hot destination by attracting foreign investment companies and MNCs 
(Appendix A) to set up facilities and joint ventures. The shift toward research driven market 
is getting its momentum from the large inflow of foreign funds (100% FDI investment 
allowed ± section 4.3.2). The government of India has taken the initiative to restructure the 
regulatory policies in order to assist R & D and manufacturing industries. These market 
conditions make it ideal for companies and research institutes to invest time and effort in this 
sector. 
In the global wound management market segment has a lot of potential in the China, UK and 
India. The Chinese Biotechnology industry is leading in terms of revenue generation. UK 
market has shown great potential for growth and accounts 2nd in the overall Biotechnology 
revenue generation in whole of Europe. However in UK the pricing of the product would 
have less impact as the nation displays very low price sensitivity as the state run health 
services (NHS) will aim to keep their spending low. The new wound management product 
made by cyogel sheets would have a very high demand in UK as it has the properties of 
Hydrocolloids (account to 33.8% of market share) and Hydrogel sheets (account to 10.6% of 
the UK product market share). Also, the burn statistics has worsened YoY (Appendix D). In 
Nottingham alone the 3rd degree burns accounted to 25% of the burns in 2007 which 
increased to 28% in 2008. Among all the burn cases in Nottingham city, 40% account to 2nd 
degree burns (Appendix E). 
The DBT in India is the backbone for Biotechnology as it accounts for policy making, 
promotions of R&D, international co-operation and manufacturing activities. The 
institutional framework and the funding opportunities are enormous unlike in other 
developing countries. The history of Venture capital investors further reinstates the argument. 
Government initiatives like the National Biotech Development Strategy that lay a roadmap 
for the next 10 year in the field of Regenerative Medicine and Bioengineering is encouraging 
for acadamia and companies to carry out research work and launch products with cutting 
edge technologies. Once the new skin regenerative product goes through all the clinical trials 
successfully, it should be in a good position to tap that 80% of unmet demand for wound care 
in India (section 4.3.3). 
6.1. Literature review and empirical evidence 
In the previous chapter, it was discussed that it is important for the product to be of good 
quality rather than reaching the market the quickest. It was found that the team in IIT has this 
as their motto and is focused on extensive research on regenerative template and the dressing 
material. Cryogellation, which is a part of Cell encapsulation techniques (discussed in section 
2.3) is used in developing this template. An extensive backward roadmapping was done to 
Gelatin based skin regenerating template: Market Research and Product Analysis 
 
 
Arjun G. Reddy   52 
 
understand the demand for the skin regenerative products in India. The price oriented 
population was the target. The technology push happening at the moment is a Cryogelation 
technology where the process is patented to IIT, Kanpur. This techniques helps in creating a 
gelatin based skin regenerative template with good interconnectivity between the pores and 
thereby making it a very good medium for the cells to be absorbed and then multiply. 
The tests conducted at the moment are only laboratory based. Initial tests have already proved 
that the new product has a very good absorption capacity; extent of natural tissue replacement 
is phenomenal with the ability to retain differentiated cells. The tests have also shown the 
ability of the new product to retain its shape after implantation in the host. Animal testing 
would be the next step followed by the clinical trials. This indicates that the product is very 
much in the preclinical phase of its life cycle. Although the product is very promising, the 
only disadvantage is that it would take a minimum of 5 years before it reaches the market. 
The results of clinical trials phase would be crucial in determining the technology pull. 
It was observed, while interviewing various surgeons in India, that lack of awareness of the 
product's characteristics played an important role in creating the demand for the product. 
Most of the Indian products like Hellicol were not used in Victoria Hospital only because the 
surgeons were not aware of the advantages of using it instead of a plain collagen sheet. To 
prevent such problems, the new regenerating graft must look at making technical flow of 
information in parallel to the order information. Since it is one of the kind, it would be even 
more important to inform physicians and surgeons about the usage. 
There are no skin regeneration products in the market which are made of gelatin. This main 
difference alone is a strong point for product differentiation that was discussed as essential (in 
the literature review section) for pricing it either high or low. Based on analysis of other 
products, the competitive response is likely to be very low for many years to come. 
Therefore, a company owning this product has the liberty of pricing the new skin 
regenerative product over a broad range of pricing. 
A rough business forecast on the pricing was done based on the market analysis and industry 
standard. The price of the new Skin regenerative product is indeed competitive. However, in 
reality there are several other aspects that need to be considered. The accuracy depends on 
how the technical and manufacturing personal on the product development team assesses per-
unit costs. The difference between the revenue and cost of goods sold is the gross margin 
available to cover fixed costs and contribute to profits. Although the price of the new product 
is estimated around Rs. 40 for a 10 x10 cm sheet, a company owning the product could 
increase the price further up, but still lower than the competitor's pricing, and have huge 
positive difference in revenues and cost of goods. This would in turn contribute to huge 
profits for the company. 
The costs incurred for R & D and concept testing, as well as anticipated costs for prototype 
development, equipment and materials, labor, product testing, and additional market research 
would all attribute to the development costs. Since the product has to go through clinical 
trials, it would involve additional capital expenditure. Once the clinical trials are successful, 
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marketing costs start at the prelaunch. These would include advertising, distribution, sales 
promotion, sales force coverage, miscellaneous selling and communication costs. An 
RYHUKHDGZLOODOVRKDYHWREHDOORFDWHGIRUDGPLQLVWUDWLYHFRVWV5HJDUGOHVVRIWKHFRPSDQ\¶V
attitude toward cost allocation, it is imperative that the estimated revenue (either price or 
number of units) is not artificially inflated simply to cover these costs. The amount that 
finally remains after subtracting the development costs, marketing costs and the overhead 
costs is the gross profit. This is where the product is expected to contribute to indirect fixed 
costs, taxes and profit. In this case, it appears to have a potential for huge profits. 
6.2. External factors in decision-making 
Approval from Drug Control General of India is essential for initiation of clinical trials: 
For approval purposes, clinical trials can be classified as (Pharmabiz, 2009) 
- Category A: In this category the approval time is around 2-4 weeks and it includes 
clinical trials whose protocols have been approved by USA, UK, Switzerland, 
Australia, Canada, Germany, South Africa, Japan or the EMEA. 
- Category B: The regulatory turnaround time in this category would be around 8-
12 weeks. It includes clinical trial protocols which have been approved in a 
country that is not listed in Category A. 
Clinical research organizations (CROs) have to obtain 'no objection' letter from Drugs 
Controller General of India(DCGI) and import license to import the research drug. If the 
samples have to be exported (UK or China) then export license is required from Directorate 
General of Foreign Trade (DGFT). Also, Registration of trials involving humans has been 
made mandatory starting in June 2009 on the Clinical Trials Registry-India (CTRI) website 
(livemint & wall street journal, 2009) 
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Chapter 7: Conclusion & Recommendation 
To identify the criticality of a success factor, measuring the performance of the new skin 
regenerative product is needed. In the biopharmaceutical R&D business, it is difficult to 
measure performance. In an early phase when speculating whether a product will survive and 
do well in the global competition as desired, there are usually no products in the market and 
little, if any, positive cash flow for years to come. However, some benchmarks for successful 
performance could be identified: 
- Receiving venture capital (VC) funding 
- Collaborating with a partner 
- Conducting a successful initial public offering (IPO) 
- Having a product candidate complete a successful clinical trial 
- Finally, launching a product into the market 
 
Again, collaborating with a partner can be both a measure of performance and a CSF. It 
measures performance in the sense that the partner has considered the company to be a 
valuable ally and the co-project to be worth the risk. Or, it can be a CSF in the sense of 
gaining resources and experience essential to making the project under collaboration succeed 
and at the same time making the company succeed. A successful IPO indicates a good 
company in the sense of public evaluation. At the same time it creates cash inflow important 
IRUWKHFRPSDQ\,VPRQH\DVXFFHVVIDFWRU",WVXUHO\LVFULWLFDOIRUWKHFRPSDQ\¶VH[LVWHQce. 
Capital from VCs or IPOs and cash inflow from product sales are considered to be the 
RXWFRPHRIKDYLQJWKHµULJKW¶VXFFHVVIDFWRUVLQWKHFRPSDQ\QRWPHUHO\VXFFHVVIDFWRUVSHU
se. 
Exploring Industry Schemes: Small Business Innovation Research Initiative (SBIRI) is the 
first scheme initiated by the Department of Biotechnology, India in 2006-07 for encouraging 
the small and medium enterprises to take innovative, high risk R&D projects for establishing 
proof of concept as well as for development and commercialization of research leads having 
market demands. The proposals under the SBIRI scheme are funded in two phases i.e., Phase- 
I & Phase-II. Under Phase ± I, risky but innovative, early stage, pre-proof-of-concept R&D at 
lab scale is funded; while in Phase-II, support is for validation, scale-up, process & product 
development and commercialization. The support from the department under the scheme does 
not involve cost of land & building. The funding pattern under Phase-I and Phase-II are 
available at www.dbtindia.nic.in . Since its inception, about 500 proposals have been 
received in nine batches. 
Area-wise percentage is as follows: 
ͻ Health-47%, 
ͻ Agriculture-20%, 
ͻ Industrial products and processes-18%, 
ͻ Instrumentation and devices-6.5%, 
ͻ Environmental biotechnology-3.7%, 
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x Food & Nutritional Biotechnology, 
x Bioinformatics and other areas-4.8%. 
The most important point to note is that under health (47%), few early leads from SBI 
Projects are: 
ͻ A silk protein blend film-for burn wound management 
ͻ A homologous natural bio-material for treating cancer lesions & burn wounds 
So far 48 projects have been sanctioned. During 2008-09, 12 projects were sanctioned out of 
87 proposal received in two batches. SBIRI scheme has been well received. A review 
undertaken by IIM, Bangalore has suggested to accommodate broader range of bio-tech 
LQGXVWULHVHQVXULQJWKDWPRUH60(¶VDUHEHQHILWHGDVDOVRQDWLRQDOO\UHOHYDQWSURMHFWVFRXOG
be implemented. 
Further details could be obtained on url: http://dbtindia.nic.in/uniquepage.asp?ID_PK=36  
Indo-UK: DBT-Welcome Trust Fellowship Scheme in Biomedical Research: Since the 
new bio-pharma product is in the lab phase undergoing lab tests there is a lot of scope for 
research activities. Indian Biotechnology department's endeavour for international 
cooperation and partnerships to attain global recognition, exploring mutually advantageous 
science collaboration and meeting international standards could be of great assistance. The 
Department of Biotechnology in India has partnered with Welcome Trust (WT), UK to 
launch a three-tier fellowship programme on biomedical research at postdoctoral level. The 
Welcome Trust is an independent charity funding research to improve human and animal 
health. The DBT and the Welcome Trust each have committed £8 million per year, for a 
period of ten years. The scheme is devised to support basic, clinical and veterinary research. 
Details of the Alliance are available at www.wellcomedbt.org. 
Major factors limiting the growth of indigenous medical devices industry are the high cost 
and non-availability of imported technology, higher risks involved in producing and 
marketing medical devices, inadequate indigenous technology development and production 
of biomaterials and device and lack of a regulatory authority for medical devices in the 
country. 
The research area that is currently being pursued in IIT Kanpur seems to offer excellent 
revenue and profit potential. However, during the path towards its launch in the market it is 
essential to have a closer tracking of profiles and related research programs and academe. In 
addition, they will also have to pay more attention to economics of drug development 
process. A product patent is granted for a period of 20 years. Taking a Bio-Pharma product 
from drug discovery stage to market takes anywhere between 7 to 10 years, leaving about 10 
years for recouping investment. Besides identifying the research area (which is already done 
in this case), managing the drug development process is critical skills that the research 
institute need to acquire. Reducing time-to-market is as important as discovering new grafts 
as alternatives for existing expensive products. However, time-to-market is even more 
important for Bio-Pharma products that are new to the industry and segment like the gelatin 
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based product. In the generics market, market exclusivity period has assumed great 
importance. The first company to enter the market will get to enjoy a premium. Therefore, 
new product development plays even more critical role in the generics market.  
The cost of producing a marketable pharmaceutical product has increased sharply in recent 
years due to greater regulatory control, increased competition and globalization. Now, more 
than ever, pharmaceutical companies must outsource research and development works to 
their biotechnology counterparts² and they are doing so in record numbers. Pharmaceutical 
companies bring to these partnerships is the ability to navigate regulations minefield and of 
course, marketing expertise. 
Academic collaborations with industry are a win-win deal for both. Academia gets the much 
needed funding for research while the industry can lay its hands on breakthroughs as soon as 
they occur. Alliances for manufacturing can also be a beneficial for both the parties where the 
manufacturer will be able to concentrate on core manufacturing at a lower cost which 
advantage could be enjoyed by the partner company. Players who are producing in bulk (skin 
regenerative grafts) by tying a long term contracts through alliances could de-risk their 
business²resulting in a smooth revenue flow. In this case by collaborations with industry, 
IIT Kanpur can offer breakthrough research and insights into Wound care and burn care 
treatment. As major markets are highly regulated and lucrative, the quality standards are a 
must to enter those markets. Standards such as Good Manufacturing Practices and Good 
Clinical Practices will become a must in the years to come. 
While numerous advances have been made in the science of biological tissue engineering in 
the past few decades, the ideal skin replacement remains elusive. None of the currently 
available products in the market IXOILOO DOO WKH FULWHULD RI D ³SHUIHFW´ VNLQ UHSODFHPHQW
Currently, the patieQW¶VVNLQUHPDLQVWKHEHVWDOWHUQDWLYHWRUHSODFHEXUQHGWLVVXHVThe advent 
of the new µDOO-in-RQH¶ JHODWLQ EDVHG skin regenerative product with the aim of providing 
µZRXQGDHVWKHWLF ORRN¶ZLOOXQGRXEWHGO\ EHFRPHDQ ideal skin replacement. This diligently 
pursued applied research skin regenerative product is on the right course to be proved as a 
perfect replacement sooner rather than later. 
7.1 Area of future research 
Technical aspects of the product: 
After interviewing the team in IIT lab, the results of the lab tests done so far were positive. 
However, the skin regenerating graft has to undergo several other lab tests before the clinical 
trials. 
For the PVP layer 
(1) Ability to detoxify and prolong the activity of Iodine 
(2) Controlled release of Iodine in skin injuries 
(3) Trying to minimize the toxicity of Iodine. 
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For the Regenerative Gelatin Layer 
(1) Studies in animal models to minimize scar formation or avascularisation 
(2) Inducing nerve growth and 
(3) Effectiveness of gelatin on humans 
(4) Hair regeneration using stem cells 
Business aspects of the product: 
Understanding the operational and marketing challenges faced by the Skin Regeneration 
grafts that are currently popular in India. For ex: Hellicoll. 
Exploring the reasons for long delays in the clinical trials in India and how to overcome 
them? 
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Appendix 
 
Source: Datamonitor 2008, Global Pharmaceuticals, Biotechnology & Life Sciences 
Appendix A: Industry Group Share: % Share, by Value, 2008 
 
Distribution of Medically Certified Burn Deaths by Age and Sex in Delhi 
 (1991 to 2002, 2004 and 2005) 
Year 
Below 14 Years 15-24 Years 25-44 Years 45-64 Years 65 & Above Total 
Male Female Male Female Male Female Male Female Male Female Male Female 
1991 93 82 166 385 249 492 59 54 13 24 580 1037 
1992 81 99 18 324 197 337 48 48 18 30 462 838 
1993 81 98 130 400 258 396 50 54 17 27 236 975 
1994 94 111 131 415 279 464 46 58 24 25 574 1073 
1995 77 104 156 404 298 376 59 69 17 32 607 985 
1996 4 6 20 44 38 71 8 8 8 7 78 136 
1997 8 16 25 55 50 92 16 25 27 27 126 215 
1998 28 30 39 164 105 190 22 13 18 13 212 410 
1999 23 30 61 141 128 165 20 19 6 5 238 360 
2000 12 11 11 39 21 47 7 7 258 318 309 422 
2001 81 85 119 224 191 334 47 45 45 58 483 766 
2002 27 33 57 100 84 132 28 24 32 58 228 347 
2004 44 37 69 158 122 155 33 18 4 4 272 372 
2005 76 65 104 207 177 229 73 60 31 42 461 603 
Appendix B: Burn Deaths by age and sex in Delhi. Source : Directorate of Economics and 
Statistics, Govt. of Delhi. 
Cause/State/Sex-wise Medically Certified Deaths by Diseases of Skin and Subcutaneous Tissue in 
India - Part I 
(1997) 
M.G./ 
CAT/ 
SC 
Cause of Death Sex India Andhra Pradesh Goa 
Har- 
yana 
Himachal 
Pradesh 
Karna- 
taka Kerala 
Madhya 
Pradesh 
Maha- 
rashtra 
Mani- 
pur 
XII Diseases of the Skin and Subcutaneous Tissue (680-709) 
M 457 8 0 14 0 107 10 37 116 0 
F 303 6 1 1 0 42 6 15 121 3 
  
Diseases of Skin and 
Subcutaneous Tissue (680-709) 
M 457 8 0 14 0 107 10 37 116 0 
F 303 6 1 1 0 42 6 15 121 3 
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1 Infections of Skin and Subcutaneous tissue (680-686) 
M 304 6 0 9 0 79 6 37 105 0 
F 166 4 1 1 0 23 6 13 96 0 
2 All other diseases of skin and 
subcutaneous tissue (690-709) 
M 153 2 0 5 0 28 4 0 11 0 
F 137 2 0 0 0 19 0 2 25 3 
.. contd 
Cause/State/Sex-wise Medically Certified Deaths by Diseases of Skin and Subcutaneous Tissue in 
India - Part II 
(1997) 
M.G./ 
CAT/ 
SC 
Cause of Death Sex Megha- laya 
Naga- 
land Orissa 
Pun- 
jab 
Rajas- 
than 
Tamil 
Nadu 
Tri- 
pura 
Uttar 
Pradesh 
Andaman & 
Nicobar Islands Delhi 
Pondi- 
cherry 
XII 
Diseases of the Skin and 
Subcutaneous Tissue (680-
709) 
M 0 0 26 6 8 98 0 5 0 22 0 
F 0 0 9 3 0 82 0 3 0 10 1 
  
Diseases of Skin and 
Subcutaneous Tissue (680-
709) 
M 0 0 26 6 8 98 0 5 0 22 0 
F 0 0 9 3 0 82 0 3 0 10 1 
1 Infections of Skin and Subcutaneous tissue (680-686) 
M 0 0 24 4 6 2 0 4 0 22 0 
F 0 0 8 0 0 3 0 2 0 9 0 
2 All other diseases of skin and 
subcutaneous tissue (690-709) 
M 0 0 2 2 2 96 0 1 0 0 0 
F 0 0 1 3 0 79 0 1 0 1 1 
Appendix C: National List for Tabulation of Mortality and Morbidity 
Leading Causes of Death 
Source : Medical Certification of Cause of Death 1997, Ministry of Home Affairs.  
 
Appendix D: Total number of burn injuries in UK. Source: International Burn Injuries 
Database, 2007 
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Appendix E: Burns Statistics in Nottingham Source: NHS, Nottingham 
 
Appendix F: Top Therapeutic segment in India 
Appendix G: There are six regulatory bodies in India, of which one or more deal with many of aspects 
of biotechnology in the country. They are 
ͻ Department of Biotechnology, Ministry of Science and Technology - which is the administrative 
body of regulatory approvals for investment and technology activities in the sector.  
ͻ Drug Controller General of India, Ministry of Health - which is the official regulatory body 
governing manufacture and commercial release of pharmaceutical products, including 
recombinant products. 
ͻ Genetic Engineering Approvals Committee, Ministry of Environment and Forests ± which deals 
with bio-safety aspects and is the regulatory authority for trials and commercial release of all 
GMOs.  
ͻ Ministry of Chemicals and Pharmaceuticals - which is the administrative ministry for the 
chemical and pharmaceutical industry and governs industrial regulation and foreign investment in 
these sectors (enzymes. Pharma, industrial biotech products, etc).  
ͻ Department of Animal Welfare - Ministry of Health, which deals with the protection of animal 
rights and use of animals for scientific research experiments. 
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ͻ Department of Agriculture Research and Education, Ministry of Agriculture - which deals 
with all field research in agriculture crops. 
 
 
Appendix H: Regulatory Regime of Biotechnology in India. Source: www.dbt.nic.ac 
